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L-Glutamate is the major excitatory neurotransmitter in the mammalian CNS that can
mechanistically contribute to either neuronal signaling or neuronal pathology.
Consequently, its concentration in the CNS must be carefully regulated, a critical need
that is met by the excitatory amino acid transporters (EAATs). The presence of at least
five isoforms of EAATs raises interesting questions as to potential structural and
functional differences among the subtypes. We have investigated possible differences in
the ligand binding domains of the EAATs through the development of computationally
based pharmacophore models. An EAAT2-specific model was created with four potent
and selective ligands that act as non-substrate inhibitors: cis-5-methyl-L-trans-2,3pyrrolidine dicarboxylate, L-anti-endo-3,4-methano-pyrrolidine-3,4-dicarboxylate (Lanti-endo-3,4-MPDC), (2S,3R,4S)-2-(carboxy-cyclopropyl) glycine (L-CCG-IV) and Lβ-threo-benzyloxy-aspartate (L-β-TBOA). This model predicts distinct regions that might
influence the potency and selectivity of EAAT2 ligands, including: 1) a highly conserved
positioning of the two carboxylate and the amino groups, 2) a nearby region that can
accommodate selective modifications (e.g., cyclopropyl ring, CH3 groups, and O atoms),
and 3) a region occupied by the benzyl ring of L-β-TBOA. This model was also used in
conjunction with L-β−threo-benzyl aspartate (L-β-TBA), a recently characterized
preferential inhibitor of EAAT3, to identify possible differences between EAAT2 and
EAAT3.
Functional studies on the EAATs also led to the identification of a putative modulatory
mechanism that is specific for EAAT1. Thus, a series of sulfated neuroactive steroids,
including pregnenolone sulfate (PREGS), were found to selectively increase the ability of
EAAT1 to transport atypical substrates like D-aspartate and L-cysteine, but not Lglutamate. The effect was rapid, reversible, limited to a select group of sulfated steroids,
and not observed with either EAAT2 or EAAT3. Interestingly, the action of PREGS
could be blocked by the simultaneous addition of arachidonic acid, a previously
recognized inhibitory modulator of EAAT1. The fact that this observed change in
activity was produced by neurosteroids raises questions not only related to the regulatory
mechanisms itself, but also to the possible role of neurosteroid in modulating glutamate
transport.
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Chapter 1: Background and Significance:
The amino acid L-glutamate was first shown to excite spinal neurons in 1959 (Curtis et
al., 1959). Since that time it has been shown to act in all the regions of the brain and is
now accepted as the major excitatory amino acid neurotransmitter in mammalian CNS.
Through activation of various ionotropic and metabotropic receptors in the CNS
(Monaghan et al., 1989; Nakanishi et al., 1998; Cotman et al., 1987; Wollmuth and
Sobolevsky, 2004), L-glutamate participates in most aspects of normal brain function
including fast synaptic transmission, cognition, memory and learning (Fonnum, 1984;
Collingridge and Lester, 1989; Hollmann and Heinemann, 1994; Mayer and Armstrong,
2004).

The concentration of L-glutamate in the brain is estimated to be 5-15 mmol per kg weight
depending on the region (Schousboe, 1981; Krnjevic, 1970). However, the highest
concentrations are found inside nerve terminals (~ 10 mM) (Ottersen et al., 1992;
Ottersen et al., 1996) and the estimates of the concentration of glutamate in synaptic
vesicles range from 60-210mM (Nicholls and Attwell, 1990; Burger et al., 1989; Riveros
et al., 1986). The concentrations in extracellular fluid and in the cerebrospinal fluid are
typically reported to be between 3 and 10 µM (Hamberger and Nystrom, 1984; Lehmann
et al., 1983). This means that the concentration gradient of glutamate across the plasma
membranes is at least several thousand-fold (Storm-Mathisen et al., 1983; Ottersen et al.,
1992; Ottersen et al., 1996). Moreover, low micromolar concentrations of glutamate have
the ability to activate both ionotropic receptors (Patneau and Mayer, 1990; Curras and
Dingledine, 1992) and metabotropic receptors (Schoepp et al., 1999). The average
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concentration of glutamate attained in the cleft following synaptic release has been
estimated to be about 3mM (Clements, 1996; Diamond and Jahr, 1997; Harris and Sultan,
1995) which is enough to saturate and activate postsynaptic receptors at hippocampal
synapses (Clements et al., 1992). Excessive activation of glutamate receptors can be
neurotoxic, a phenomenon termed excitotoxicity (Olney, 1990), (Choi and Rothman,
1990; Choi, 1992; Meldrum, 1993; Doble, 1999). Disruptions in glutamate homeostasis
have been implicated in various pathologic conditions, including: epilepsy, ALS,
dementia, ischemia, brain and spinal cord injuries and hypoglycemia (Doble, 1999).
Given both the excitatory and excitotoxic properties of L-glutamate, it is not surprising
that its concentration within the CNS must be carefully regulated. This activity is
ascribed to glutamate transporters found on both the neurons and glia (Gegelashvili and
Schousboe, 1997; Kanai and Hediger, 2003).

Although glutamate is present in all cells, its release through exocytosis requires active
transport into secretory vesicles. Three subtypes of vesicular glutamate transporters
(VGLUTs) have been identified that concentrate glutamate into neurosecretory vesicles
for regulated release. VGLUTs belong to SLC17A group (Reimer and Edwards, 2004)
and includes VGLUT1 (SLC17A6), VGLUT2 (SLC17A7) and VGLUT3 (SLC17A8)
(Bellocchio et al., 2000; Takamori et al., 2002; Takamori et al., 2000; Takamori et al.,
2001; Aihara et al., 2000; Fremeau et al., 2001; Kaneko and Fujiyama, 2002). These
transmembrane proteins are thought to have 6-12 predicted transmembrane domains.
VGLUT activity is coupled to the proton electrochemical gradient (∆µH+) generated by a
vacuolar type H+-ATPase (Moriyama et al., 1992; Bellocchio et al., 2000; Forgac, 2000).
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VGLUTs transport glutamate with an affinity (Km ~ 1mM) that is 100- to 1000-fold
lower than that of the high affinity glutamate transporters present on the plasma
membrane. Additionally, in contrast to the plasma membrane glutamate uptake, these
vesicular counterparts do not transport aspartate. Vesicular transporters have a biphasic
dependence on Cl-, such that low concentrations activate uptake while high
concentrations are inhibitory (Reimer et al., 2001; Shigeri et al., 2004).

Glutamate Receptors:
Glutamate receptors can be broadly divided into two major classes, ionotropic and
metabotropic. The ionotropic receptors (iGluRs), also called ligand-gated ion channels
(LGIC), are intrinsic transmembrane ion channels that open in response to the binding of
a chemical messenger (in this case, glutamate). They are responsible for rapid signaling
and produce relatively large conductance changes. On the other hand, the metabotropic
glutamate receptors (mGluRs) belong to G protein-coupled receptor (GPCR) family as
their signal is produced via guanine nucleotide-binding protein (or G-protein) linked to
second messenger systems.

Ionotropic Glutamate Receptors: Three major subtypes of ionotropic glutamate
receptors have been identified and named after the selective agonists that were used to
pharmacologically distinguish them from one another (Monaghan et al., 1987;
Collingridge et al., 1989). They include NMDA (N-methyl-D-aspartate), AMPA (αamino-3-hydroxy-5-methylisoxazole-4-propionic acid) and KA (kainate), receptors. The
binding of glutamate to the ionotropic receptors produces an excitatory postsynaptic
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potential as a consequence of the opening of glutamate-gated ion channels permeable to
both Na+ and K+ (Nicholls and Attwell, 1990), (Hosli et al., 1976). NMDA receptors are
selectively blocked by the drug APV (2-amino-5-phosphonovaleric acid). The AMPA
and kainate receptors are not affected by APV, but both are blocked by the
dihydroquinoxaline derivatives like 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and
6,7-dinitroquinoxaline-2,3-dione (DNQX) (Kew and Kemp, 2005). Thus, the AMPA and
kainate receptors have historically been referred to as non-NMDA receptors.
The ionotropic glutamate receptors are complexes of four subunits. Each subunit has a
ligand-binding domain and possesses four membrane-associated segments (3
transmembrane and 1 reentrant loop). The channel-lining TM2 segment forms a loop and
reexits into the cytoplasm (Wo and Oswald, 1995), (Wood et al., 1995).

NMDA receptor: NMDA-type channels open and close relatively slowly in response to
glutamate and thereby contribute to the late phase of the EPSP (Hestrin et al., 1990). The
NMDA receptor contains a cation channel that is permeable to Na+, Ca2+ and K+ (Hosli et
al., 1976; Dingledine et al., 1999; Mayer and Armstrong, 2004). In particular, the Ca2+premeability for NMDA receptors appears to be much higher than that of non-NMDA
glutamate receptor subtypes (McBain and Mayer, 1994) and other cation-selective
receptors (Rogers and Dani, 1995).

NMDA receptor channels are obligate heterotetramers requiring NR1 and NR2 subunits
to form functional channels. NR3 might also form functional channels with NR1, but it
most commonly co-assembles with NR1 and NR2 to form complexes with unique
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properties and NR3 subunit substitutes for one of the NR2 subunits. At least eight splice
variants have been identified for the NMDAR1 subunit and these variants produce
differences in the properties of the expressed receptor (Hollmann and Heinemann, 1994).
Four other members of the NMDA receptor family have been cloned (NMDAR2A-2D)
and their deduced primary structures are highly related. These four NMDA receptor
subunits do not form channels when expressed singly or in combination unless they are
co expressed with NMDAR1. Apparently, NMDAR1 contributes to the formation of an
essential functional pore by which activation of NMDA occurs, while NMDAR2
receptors 2A-2D play important roles in modulating the receptor activity when mixed as
heteromeric forms with NMDAR1 (Dingledine et al., 1999).

Various pharmacologically distinct sites that alter the activity of NMDA receptors have
been characterized. These include:
1) a glutamate binding site that promotes the opening of a high-conductance
channel that permits entry of Na+ and Ca2+ into target cells (Dingledine et al.,
1999; Mayer and Armstrong, 2004; Hosli et al., 1976).
2) a strychnine-insensitive glycine-modulatory site. Activation of NMDA
receptor channels requires binding of both L-glutamate and the co-agonist
glycine. (Kleckner and Dingledine, 1988; Johnson and Ascher, 1987).
Stoichiometrically, two molecules of NMDA and two molecules of glycine
must bind to the NMDA receptor for activation of ion channel gating in in
vitro, mouse hippocampal neurons (Benveniste and Mayer, 1991). Whereas,
glycine appears to bind at distinct regions of the NR1 subunit, glutamate
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binding resides in the homologous region of the NR2A and 2B subunits. Thus,
agonist and coagonist binding sites are located on corresponding regions of
distinct subunits of NMDA receptor channels. The crystal structure of the
NMDA ligand-binding core of NR2A bound to glutamate and that of the
NR1-NR2A heterodimer bound to glycine and glutamate confirms that these
receptors are heteromeric ion channels that for activation require binding of
glycine and glutamate to the NR1 and NR2 subunits respectively (Furukawa
et al., 2005).
3) use-dependent PCP (phencyclidine) site (also binds MK801, ketamine) which
act most effectively when the receptor is activated (Lerma et al., 1991;
MacDonald et al., 1991).
4) voltage-dependent Mg2+-binding site. The opening of NMDA receptor
channel depends on membrane voltage as well as transmitter (Nowak et al.,
1984; Mayer et al., 1984).
5) an inhibitory Zn2+ site produces voltage-independent block (Christine and
Choi, 1990; Legendre and Westbrook, 1990).
6) polyamine-regulatory site whose activation by spermine and spermidine
facilitates NMDA receptor-mediated transmission (Rock and MacDonald,
1992).

The significance of NMDA receptor is evident from its involvement in a wide range of
neurophysiological and pathological processes such as memory acquisition,
developmental plasticity, epilepsy and the neurotoxic effects of brain ischemia. Normal
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levels of NMDA receptor activity are needed to promote survival and render neurons
resistant to subsequent trauma (Hardingham and Bading, 2003). Excessive activation of
NMDA receptors can lead to excitotoxic trauma and subsequently, neuronal death. The
mechanism of cell death (apoptosis versus necrosis) is believed to depend on the severity
of the insult. Rapid, necrotic cell death occurs after acutely excessive NMDA receptor
activation. Slower apoptotic cell death occurs after a milder (although ultimately toxic)
episode of NMDA receptor activation (Hardingham and Bading, 2003).

AMPA receptor: AMPA receptors are composed of four members (GluR1-4) that are
products of separate genes. Like NMDAR, AMPAR is a tetramer of independent subunits
(Rosenmund et al., 1998). Four glutamate molecules bind to activate these receptors
(Rosenmund et al., 1998; Wollmuth and Sobolevsky, 2004). The AMPA receptor
subunits can form either functional homomeric or heteromeric channels. The GluR2
subunit plays a critical role in determination of the permeability of heteromeric receptors
to Ca2+. Thus, AMPA receptors that do not contain GluR2 are Ca2+ permeable (Hollmann
and Heinemann, 1994; Washburn et al., 1997). AMPA and quisqualate are preferred
agonists whereas 2,3-dihydro-6-nitro-7-sulfamoylbenzo quinoxaline (NBQX) (Kew and
Kemp, 2005) and 2,3-benzodiazepine derivatives (e.g., GYKI-52466) (Bleakman et al.,
1996; Rogawski, 1993) appear to be selective antagonists at AMPA receptors.

Kainate Receptors: Kainate receptors are composed of two related subunit families,
GluR5-7 and KA1 and 2. KA1 and 2 combine in heteromeric assemblies with members
of the GluR5-7 subfamily to form functional receptors. The KA1 and KA2 homomeric
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complexes have been shown to be non-functional. However, GluR5, 6 and 7 subunits can
form functional homomeric receptors. Kainate receptor forms a tetrameric complex and is
activated following the binding of four glutamate molecules (Rosenmund et al., 1998;
Wollmuth and Sobolevsky, 2004). With its nearly ubiquitous expression in the brain, the
KA2 subunit is likely a constituent of most neuronal kainate receptors (Swanson et al.,
2002). Domoate and kainate are preferred agonists for these receptors. Topiramate, an
anticonvulsant drug, has been shown to reduce seizures induced by kainic acid but not by
AMPA (Perucca, 1997; Conti et al., 2002).

Metabotropic Glutamate Receptors:
The metabotropic glutamate receptors can be selectively activated by trans-(1S, 3R)-1amino-1,3-cyclopentane dicarboxylic acid (ACPD). The action of glutamate on the
ionotropic receptors is always excitatory, while activation of the metabotropic receptors
can produce either excitation or inhibition. The widespread distribution of metabotropic
receptors in the CNS coupled with the prevalence of glutamate as a neurotransmitter
indicates that this system is a major modulator of second messengers in the mammalian
CNS (Kew and Kemp, 2005).

The mGlu receptors are divided into three major groups on the basis of sequence
homology, pharmacological profile, and second messenger coupling (Schoepp et al.,
1999),(Kew and Kemp, 2005). Molecular cloning studies have revealed the existence of
at least eight different subtypes of mGluR, mGluR1-mGluR8, which have a common
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structure of a large extracellular domain preceded by the seven-membrane spanning
domains.

Group I (mGluR1 and mGluR5) is coupled to stimulation of phosphotidylinositol
hydrolysis/ Ca2+ signal transduction. Group II (mGluR2 and mGluR3) is negatively
coupled through adenylyl cyclase to cyclic adenosine monophosphate formation. Group
III (mGluR4, mGluR6-8) is also negatively linked to adenylyl cyclase activity but shows
a different agonist preference from that of mGluR2 and 3. L-AP-4 (L-2-amino-4phosphonobutyrate) is a potent agonist of mGluR4, 6, 7 and 8 but has little effect on other
receptor subtypes. These receptors are shown to be involved in physiological and
pathological conditions such as synaptic plasticity (Endoh, 2004; Bonsi et al., 2005),
neurotoxicity and neuroprotection (Baskys et al., 2005), and drug addiction (Robbe et al.,
2002).

Glutamate Transporters:
The excitatory signal is terminated by the high-affinity uptake of glutamate from the
synapse by the glutamate transporters present in both astrocytes and neurons. In
astrocytes, glutamate is taken up from the extracellular fluid and converted to glutamine
by astrocyte-specific enzyme glutamine synthetase (GS) (Martinez-Hernandez et al.,
1977). Glutamine has been reported to be critical for the maintenance of a normal level of
glutamate in nerve terminals (Laake et al., 1995). Glutamine is released in the
extracellular fluid, taken up by neurons and reconverted to glutamate by the phosphatedependent mitochondrial enzyme glutaminase (Hertz et al., 1999; Magistretti et al., 1999;
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Broer and Brookes, 2001; Kvamme et al., 2001). This metabolic pathway is referred to as
‘glutamate-glutamine cycle’.

Glutamate Transporter Family: High-affinity sodium dependent glutamate transporters
belong to the solute carrier family 1 (SLC1) that includes five eukaryotic glutamate
transporters and two eukaryotic neutral amino acid uptake systems (Kanai and Hediger,
2003; Danbolt, 2001; Slotboom et al., 1999). The glutamate transporters contain between
500 – 600 amino acid residues (~65 kDa).

The neurotransmitter transporters are all ion-coupled carriers that mediate the
accumulation of the neurotransmitter substrate using the movement of one or more ions
down their concentration gradients. While these transporters are not directly coupled to
the hydrolysis of ATP, they are indirectly coupled through the ion gradients generated by
ion-pumping ATPases (Glynn and Karlish, 1975; Lingrel and Kuntzweiler, 1994). Thus,
the plasma membrane transporters are indirectly driven by the Na+/K+ ATPase (Broer,
2002; Palacin et al., 1998) that generates gradients of Na+ (out > in) and K+ (in > out) and
in the process creates a membrane potential (∆ψ, inside negative).

Initially, three glutamate transporters were identified by molecular cloning in 1992 in
different laboratories at almost the same time. The L-glutamate/ L-aspartate transporter
(GLAST) was isolated from the rat brain cDNA library (Storck et al., 1992). In situ
hybridization revealed a high-density of GLAST mRNA in the Purkinje cell layer of
cerebellum and less dense distribution throughout the cerebrum (Storck et al., 1992).
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Glutamate transporter (GLT-1) was isolated from rat brain (Pines G, 1992). More
recently, pharmacologically indistinguishable splice variants of GLT-1, referred to, as
GLT-1b and GLT-1c have been isolated from rat forebrain and retina respectively (Chen
et al., 2002; Rauen et al., 2004). EAAC1 was isolated from rabbit intestine using an
expression cloning approach (Kanai, 1992). Subsequently, utilizing molecular cloning
and functional expression, three homologous glutamate transporters, EAAT1 (GLAST /
SLC1A3), EAAT3 (GLT-1 / SLC1A2) and EAAT3 (EAAC1 / SLC1A1), were isolated
from human motor cortex (Arriza et al., 1994). Later, EAAT4 (SLC1A6) was isolated
from the cerebellum and showed 65%, 41% and 48% amino-acid identity to the human
glutamate transporters EAAT1, 2 and 3 respectively (Fairman, 1995). Screening a human
retinal cDNA library has lead to the identification of EAAT5 (SLC1A7) (Arriza et al.,
1997). Additionally, the human counterparts of GLT-1b and GLT-1c have also been
identified from human brain and retina respectively (Lauriat et al., 2007; Rauen et al.,
2004). The different EAAT subtypes exhibit 44-55% amino acid sequence identity with
each other (Kanai and MA, 2003). For the purpose of clarity the EAAT nomenclature
will be used throughout this dissertation.

Among the five glutamate transporter subtypes, EAAT2 (GLT-1) has been shown to be
the major transporter and is responsible for over 90% of glutamate uptake in the rat
forebrain (Haugeto et al., 1996; Tanaka et al., 1997).

EAAT Localization: EAAT2 (GLT-1) and EAAT1 (GLAST) are considered to be
primarily localized to astroglia. The EAAT2 (GLT-1) protein has been found in
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astrocytes in the normal adult rat brain and spinal cord (Rothstein et al., 1994; Chaudhry
et al., 1995; Lehre et al., 1995; Ullensvang et al., 1997; Berger and Hediger, 2000).
Also, there are reports suggesting the expression of EAAT2 (GLT-1) in hippocampal
neurons (Chen et al., 2004). While EAAT2 (GLT-1) is abundant in forebrain, particularly
in hippocampus, lateral septum, cerebral cortex and striatum (Danbolt et al., 1992;
Haugeto et al., 1996; Tanaka et al., 1997), relatively lower levels are expressed in the
cerebellum (Lehre et al., 1995). Using RT-PCR and northern blotting, EAAT2b (GLT1b)
was shown to be expressed in various regions of the rat and human brain, including:
amygdala, hippocampus, nucleus accumbens and prefrontal cortex (Lauriat et al., 2007).
The third isoform, EAAT2c (GLT1c) and its human counterpart were found to be mostly
expressed in retina (Rauen et al., 2004).

EAAT1 (GLAST) is considered the major glutamate transporter in the cerebellum (Lehre
and Danbolt, 1998), the inner ear (Furness and Lehre, 1997), the circumventricular
organs (Berger and Hediger, 2000), and in the retina (Rauen, 2000). EAAT1 is most
abundant in Bergmann glia in the brain cerebellar molecular layer, but is also present in
the cortex, hippocampus and deep cerebellar nuclei. EAAT1 is expressed throughout the
CNS, but in different amounts in different regions. EAAT1 is expressed primarily in
astroglial cells (Rothstein et al., 1995; Chaudhry et al., 1995; Lehre et al., 1995; Schmitt
et al., 1997). EAAT1 (GLAST) and EAAT2 (GLT-1) have been shown to be expressed
by the same astrocytes (Lehre et al., 1995; Haugeto et al., 1996) but in different
proportions throughout the brain (Lehre et al., 1995) and coexist in the same astroglial
cell membranes as separate homo-oligomeric complexes (Haugeto et al., 1996).

12

However, GLT and GLAST have also been observed in morphologically distinct
astrocytes in primary hippocampal cultures (Perego et al., 2000).

EAAT3 (EAAC1) is mostly expressed in neurons, such as large pyramidal cortical
neurons and Purkinje cells, but does not appear to be necessarily selective for
glutamatergic neurons. It is highly enriched in the cortex, hippocampus and caudateputamen and is confined to pre- and postsynaptic elements (Kanai, 1992; Rothstein et al.,
1994; Conti et al., 1998; Kugler and Schmitt, 1999). However, some astroglial expression
has been reported (Conti et al., 1998; Kugler and Schmitt, 1999).

EAAT4 is most abundant in the Purkinje cells of the cerebellar molecular layer in adult
CNS of the rat (Nagao et al., 1997; Dehnes et al., 1998) and human (Fairman, 1995;
Furuta et al., 1997; Bar-Peled et al., 1997; Otis and Jahr, 1998).

While EAAT5 shows strong signal in retina, its expression in the brain has not been
detected (Arriza et al., 1997; Eliasof et al., 1998a; Eliasof et al., 1998b).

Stoichiometry: Glutamate transport across the plasma membrane is coupled with the
movement of the inorganic ions, thus, utilizing the free energy stored in their
electrochemical gradients. Three sodium (Na+) ions and a proton are co-transported with
each molecule of glutamate while one potassium (K+) ion is counter-transported for
EAAT3 (Zerangue and Kavanaugh, 1996a), EAAT2 (Levy et al., 1998) and EAAT1
(Owe et al., 2006). Thus, the thermodynamic estimates from these studies indicate that
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EAATs could lower extracellular glutamate to a low nanomolar range (Zerangue and
Kavanaugh, 1996a; Levy et al., 1998; Owe et al., 2006). The transporter also produces a
chloride current that is activated by glutamate, but is not stoichiometrically coupled to
glutamate transport. This anion flux follows its own transmembrane electrochemical
potential gradient (Fairman, 1995; Wadiche et al., 1995; Eliasof and Jahr, 1996; Billups
et al., 1996). The importance of the anion channel is beginning to be recognized and
EAAT5 has been shown to exhibit autoreceptor properties caused by hyperpolarization
by chloride ions in the retinal bipolar cells (Veruki et al., 2006).

Mechanisms and Structure: Uptake through the EAATs is thought to proceed through
an “alternate-access” mechanism (Jardetzky, 1966; DeFelice, 2004; Yernool et al., 2004;
Boudker et al., 2007; Koch and Larsson, 2005). The binding of extracellular glutamate
and required Na+ ions causes conformational change that exposes the substrate and ions
to intracellular milieu where they are released. Subsequently, binding of intracellular K+
ion reverts the transporter back to extracellularly open state. Accordingly, binding-sites
for glutamate and ions alternately face extracellular or cytoplasmic compartments. Within
this framework, coupling results from conformational changes induced by substrate and
ions binding (Grunewald et al., 1998; Grunewald and Kanner, 2000; Slotboom et al.,
1999; Slotboom et al., 2001; Zarbiv et al., 1998; Seal and Amara, 1998; Seal et al., 2000).
However, a clear distinction between the “rocker-switch” model (Abramson et al., 2003;
Huang et al., 2003) and “two-gated” channel model (Lester et al., 1996; Lester et al.,
1994; Cao et al., 1998; Larsson et al., 2004) has yet to be resolved. Based upon the
cysteine-scanning accessibility studies of mammalian glutamate transporters as well as
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from the 3.5Å crystal structure of archeael EAAT homologue GLTPH, it appears that
these transporters possess eight transmembrane domains along with two oppositely
oriented reentrant hairpin loops (HP1 and HP2) (Grunewald and Kanner, 2000; Yernool
et al., 2004; Seal et al., 2000). Earlier suggestions that the binding of substrate and
required Na+ ions causes conformational changes in glutamate transporters to result in
transport of the substrate (Brocke et al., 2002; Slotboom et al., 1999) was reinforced by
the recently available crystal structure (Boudker et al., 2007). The suggestion by Boudker
et al., that the extracellularly accessible HP2 loop forms the extracellular gate is
compelling. This model suggests that the binding of the substrate and Na+ ions leads to
closing of HP2 loop and subsequent transport, while binding of non substrate like L-βTBOA prevents HP2 from closing and locks the transporter in an “open” state.

EAAT glutamate transporters assemble as homotrimeric complexes (Koch and Larsson,
2005; Gendreau et al., 2004; Yernool et al., 2004; Boudker et al., 2007; Haugeto et al.,
1996). Despite the multimeric nature of the complex, the subunits seem to act
independently (Koch and Larsson, 2005; Koch et al., 2007; Leary et al., 2007; Grewer
and Rauen, 2005). However, some results suggest that glutamate carriers may interact
cooperatively during anion channel activation (Torres-Salazar and Fahlke, 2006). The
significance of the multimeric nature of glutamate transporters is still unclear. It is likely
that this assembly is important for the cell-surface expression of functional transporters.
It has also been suggested that the hydrophilic surface of the bowl formed by the
assembly of the subunits may aid in the transport of charged solute (Kavanaugh, 2004).
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EAAT Pharmacology: The presence of five glutamate transporters raises an obvious
question as to what specific physiological role each might play in defining the proper
functioning of the brain. An especially fruitful strategy to establish the roles of different
protein targets has been to pharmacologically block the corresponding proteins using
selective inhibitors and analyze the resulting effects. This approach is dependent upon the
development of subtype-selective inhibitors and substrate; which in turn, rely on a
thorough understanding of the structure-activity relationships (SAR) that govern binding
and uptake by the various EAATs. With this concept in mind, we have generated an
EAAT2 binding site-specific pharmacophore model exploiting the various features of the
diverse and relatively specific EAAT2 inhibitor profiles.

Along with L-glutamate, numerous ligands have been identified as potent, competitive
inhibitors of the EAATs (Bridges et al., 1999). Most of these identified ligands are found
to be α-amino acids and possess the second carboxylate group that is located 2-3 carbon
atoms away from the proximal carboxylate (Figure 1.1). The distance between the two
carboxylates seems to be critical. For instance, L-α-aminoadipic acid (L-α-AA), which
contains longer chain length, has been shown to be a poor inhibitor of glutamate uptake at
EAAT1, 2 and 3 (Arriza et al., 1994). Both, L-aspartate and D-aspartate were found to be
effective substrates in oocytes expressing individual glutamate transporters (Arriza et al.,
1994; Arriza et al., 1997; Fairman, 1995). However, D-glutamate was found to have
negligible activity as an inhibitor of EAATs. Thus, the stereochemistry at the α-carbon of
glutamate appears to be an important criterion for activity, although the requirement may
vary among analogues.
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Among the simple modifications made in early SAR studies, some changes to the distal
carboxylate seem to be acceptable. For example, the inhibitory activity is retained for
compound like L-serine-O-sulfate, cysteic acid and cysteine sulfinic acid, in which the
distal carboxylate of L-aspartate is replaced by sulfonate or sulfinic groups. However, the
phosphonic acid analogue, AP4, has been reported to exhibit no activity at the EAATs
(Bridges et al., 1999). Whereas L-β-TBOA blocks all subtypes, compounds like
dihydrokainate (DHK) and L-trans-2,3-PDC can selectively block EAAT2. A detailed
pharmacology is presented in the introduction to Chapter 3 of this research report. The
available structure-activity information is most advanced for EAAT2 ligands and
therefore a more extensive study has been undertaken in the present research to predict
the structural characteristics that define both the potency and specificity for this particular
transporter subtype. This was done by utilizing four relatively EAAT2-specific inhibitors
in the training set to build the pharmacophore model. The validity of this model was
confirmed by analyzing three additional inhibitors. This robust model predicted the
unique binding-site characteristics. Further, the relatively selective EAAT3 inhibitor, Lβ-threo-BA is aligned with this model to delineate the differences in the binding-sites for
EAAT2 and EAAT3 (Esslinger et al., 2005). A detailed account is presented in Chapter
3 of this dissertation.
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Figure 1.1. Simple glutamate analogues.
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Glutamate Transporter Dysfunction: Functional losses of the glutamate uptake system
can lead to cellular dysfunction and neurotoxicity either by direct action or participation
in a cascade of disruptive cellular events (Maragakis and Rothstein, 2001; Maragakis and
Rothstein, 2004). A number of pathophysiological conditions such as ALS (Rothstein et
al., 1995; Rothstein et al., 1992; Van Den Bosch et al., 2006), Alzheimer’s disease
(Masliah et al., 1996; Masliah et al., 2000), Huntington’s disease (Lievens et al., 2001),
stroke/ischemia (Rossi et al., 2000), epilepsy (Rothstein, 1996; Tanaka et al., 1997) and
schizophrenia (Ohnuma et al., 2000) have been associated with abnormal functioning of
glutamate transporters.

Regulation of EAATs: Glutamate-mediated neurotransmission is believed to involve not
only the synaptic but also extrasynaptic receptor activation. Synaptically released
glutamate has the potential to diffuse into extrasynaptic space (Scanziani et al., 1997;
Mitchell and Silver, 2000) as well as nearby synapses (DiGregorio et al., 2002). This
“spillover” of glutamate contributes to neurotransmission by acting at mGluRs and
iGluRs on both pre- and post-synaptic neurons (Brasnjo and Otis, 2001). The spillover of
glutamate has been shown to inhibit GABA release from Golgi cell terminals (Mitchell
and Silver, 2000) as well as glutamate release at mossy fiber synapse (Scanziani et al.,
1997) by activating presynaptic mGluRs. Also, it has been shown to activate
extrasynaptic NMDA receptors in mitral cells of olfactory bulb (Isaacson, 1999) and
AMPA receptors present within adjacent synapses on the granule cells of the cerebellum
(DiGregorio et al., 2002). The extent of extrasynaptic diffusion and the crosstalk between
neighboring excitatory synapses may be markedly influenced by the location and activity
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of glutamate transporters (Asztely et al., 1997). Therefore, strict regulation of glutamate
concentration is of utmost importance for normal excitatory neurotransmission.

Glutamate uptake can be regulated by a number of different pathways, including:
transcription and translation (Rothstein et al., 2005; O'Shea et al., 2006), trafficking
(Gonzalez and Robinson, 2004; Hughes et al., 2004) as well as allosteric modification of
the binding site (Vandenberg et al., 2004).

Transcription and Translation: Astrocytic EAAT2 (GLT-1) mRNA and protein are
upregulated in astrocyte-neuron co-cultures via diffusible molecules secreted by neurons
(Schlag et al., 1998). Dibutyryl cyclic adenosine monophosphate (dBcAMP) has been
shown to elevate the EAAT2 (GLT-1) protein expression in both the membrane and
cytoplasm of rat primary astrocytes (Swanson et al., 1997; Danbolt, 2001). The effects of
dBcAMP on EAAT2 (GLT-1) expression in rat cortical astrocytes are mediated through
protein kinase A and the MAP/Erk kinase pathway. Akt, also known as protein kinase B
(PKB) induces the expression of EAAT2 (GLT-1) through increased transcription
without affecting EAAT1 (GLAST) expression in astrocytes (Li et al., 2006).

EAAT expression can be regulated at the level of protein synthesis either via increased
transcription of glt1 gene (Su et al., 2003) or through increased translation of the EAAT2
transcript (Tian et al., 2007). Increased expression of glt1 gene has been found with βlactam antibiotic, ceftriaxone (Rothstein et al., 2005), and many extracellular factors,
such as EGF (Zelenaia et al., 2000), injury-induced growth factors (EGF, TGFα, FGF-2
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and PDGF) (Figiel et al., 2003; Schlüter et al., 2002), lipopolysaccharide (O'Shea et al.,
2006). Additionally, several chemical entities, including corticosterone and retinol, have
been identified that stimulate the translation of EAAT2 transcript (Tian et al., 2007).

Trafficking: In astrocyte-neuron co-cultures and C6 glioma cells expressing EAAT2
(GLT-1), activation of PKC by phorbol ester, phorbol 12-myristate 13-acetate (PMA 30′
pretreatment), causes a decrease in GLT-1 cell surface expression by interaction with the
carboxyl-terminal domain (Kalandadze et al., 2002; Zhau and Sutherland, 2004).
Unlike EAAT2 (GLT-1), EAAT3 (EAAC1) exists predominantly (>70%) in the
intracellular compartment, but can be rapidly redistributed to the cell surface when
stimulated by treatments such as platelet-derived growth factor or activation of PKC
(Sims et al., 2000; Fournier et al., 2004; Davis et al., 1998). PMA treatment causes 80%
increase in transporter activity within minutes in C6 glioma cells, which endogenously
express only EAAT3 (EAAC1). Moreover, two different PKC isozymes increase
EAAT3-mediated uptake by different mechanisms. PKCα seems to selectively increase
transporter cell surface expression. This effect is associated with redistribution of EAAT3
to the cell membrane and appears to be dependent in direct interaction of PKCα with
EAAT3 protein (Gonzalez et al., 2003). PKCε regulates uptake by a traffickingindependent mechanism, perhaps by increasing the intrinsic activity of the transporter in
C6 glioma cells (Gonzalez et al., 2002). However, this modulation of EAAT3 (EAAC1)
occurs in a cell-type specific fashion, since activation of PKC leads to opposite effects in
EAAT3 (EAAC1) expressed in different culture models. It was shown that EAAT3
(EAAC1) expressed in Xenopus oocytes is downregulated by activation of protein kinase
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C (Trotti et al., 2001). This downregulation was found to be associated with decrease in
the maximal transport rate (Vmax) and a movement of the transporter from the plasma
membrane to the intracellular compartments, with no change in the affinity for glutamate.
Another study also showed that activation of PKC induces a consistent decrease in the
activity of EAAT3 expressed in the human astrocytoma cell line U373 (Dunlop et al.,
1999). Acute treatment with PMA has been shown to cause an ~20% increase in transport
by increasing catalytic efficiency/turnover number of EAAT1 (GLAST) (Susarla et al.,
2004).

Allosteric Modification: Several compounds have been discovered that differentially
effect glutamate transporter activity by allosteric modulation. These include the effects of
arachidonic acid (Zerangue et al., 1995), zinc (Mitrovic et al., 2001), polyunsaturated
fatty acids (Fairman et al., 1998) and EAAT3 interacting protein, GTRAP3-18 (Lin et al.,
2001). Data presented in this work identify a putative modulatory site on EAAT1 that can
increase activity. Interestingly, the compounds that revealed this potential regulatory site
are all sulfated steroids.

Neuroactive Steroids: “Neuroactive steroids” is the general term that encompasses all
the steroids present in the brain. These compounds may be derived by in situ synthesis,
obtained from the peripheral hormones, or converted by enzymatic activation into active
metabolites (Paul and Purdy, 1992; Melcangi and Panzica, 2006). Moreover, neuroactive
steroids, e.g., pregnenolone (PREG), dehydroepiandrosterone (DHEA) and their sulfate
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and lipoidal esters are present in higher concentrations in tissue from the nervous system
(brain and peripheral nerves) than in the plasma (Baulieu, 1997).

In general, steroid effects can be divided into ‘genomic’ and ‘non-genomic’ mechanisms.
The genomic effects are characterized by their delayed onset and prolonged duration
while non-genomic effects are rapid in onset and short in duration (McEwen, 1994). In
the latter case, steroids can produce immediate changes (within seconds) in neuronal
excitability on a timescale that precludes a genomic locus of action. Progestins,
estrogens, androgens, and corticosteroids are capable of modifying brain functions and
behaviors by mechanisms that involve the classic genomic model for steroid action
(McEwen et al., 1983).

The non-genomic effects of neuroactive steroids are produced mainly via their action on
membrane proteins. The most thoroughly characterized membrane targets have been
GABAA, NMDA and σ receptors (Belelli and Lambert, 2005; Covey et al., 2001; Monnet
and Maurice, 2006). In particular, progesterone derivatives like 3α-hydroxy-5α-pregnan20-one (allopregnanolone) and 3α-hydroxy-5β-pregnan-20-one (pregnanolone) are
positive allosteric modulators of the γ-aminobutyric acid type A (GABAA) receptor and
negative modulators of NMDA receptors and are, therefore, considered inhibitory
steroids (Belelli and Lambert, 2005; Lambert et al., 1995; Park-Chung et al., 1994; ParkChung et al., 1997). Pregnenolone sulfate (PREGS) and dehydroepiandrosterone sulfate
(DHEAS) are negative modulators of the GABAA receptor and positive modulators of the
N-methyl-D-aspartate (NMDA) receptor and are therefore, categorized as excitatory
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neurosteroids (Covey et al., 2001; Majewska, 1992; Wu et al., 1990; Bowlby, 1993).
Additionally, the behavioral effects of PREGS and DHEAS, on memory associated with
the NMDA receptor activity appear to be influenced by their pharmacological action at σ1
sites (Monnet and Maurice, 2006; DeCoster et al., 1995; Lockhart et al., 1995; Maurice et
al., 1997).

Pharmacotherapeutic potential of Neurosteroids: Changes in neurosteroid levels are
associated with various physiological conditions, including: stress, pregnancy, neural
development and ageing (Paul and Purdy, 1992; Schumacher et al., 2003). In addition to
inducing anaesthesia, lower doses of steroid are found to produce anxiolytic, sedative and
hypnotic effects (Gasior et al., 1999; Eser et al., 2006; Rupprecht, 2003; Goodchild et al.,
2001). Data from preclinical and clinical studies support the potential efficacy of
neuroactive steroids as a novel class of drugs for the therapeutic management of epilepsy,
insomnia and drug dependence (Gasior et al., 1999; Rupprecht, 1997; Rupprecht et al.,
1996; Gee et al., 1995).

The potential that neuroactive steroids modulate different aspects of glutamatergic
signaling is a current focus of our lab. For example, Wes Smith in our lab has recently
characterized the competitive inhibition of VGLUTs by these steroids (Smith Ph.D.
dissertation, University of Montana). In the present work, we identify and characterize
the effect of some neuroactive steroids on the glutamate transporter EAAT1 using C17.2
cells and rat primary astrocyte cultures. We find that neuroactive steroid such as
pregnenolone sulfate (PREGS) can alter the transporter property of EAAT1.
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SPECIFIC AIMS

Specific Aim 1: What structural characteristics of the ligands determine the selectivity
and potency for EAAT2 (Excitatory Amino Acid Transporter 2) as determined by
molecular modeling?
a. Generate and select the most promising pharmacophore models for EAAT2
using non-transportable inhibitors by employing various superpositioning
possibilities.
b. Validate the pharmacophore models using the “leave-one-out” protocol.
Superpositioning three additional non-transportable inhibitors of EAAT2 will
test the robustness of the model. The acceptable model will generate
satisfactory scoring function values for these superpositionings.
c. Incorporate the substrate ligands into the model (from ‘a’) to elucidate the
structural and spatial features that may determine the binding and transport of
the ligands by EAAT2
d. Superposition selective ligand for EAAT3 (viz., L-β-threo-benzyl aspartate)
to delineate the points of divergence between EAAT2 and EAAT3.

Specific Aim 2: To determine the specificity with which the neurosteroids alter the
uptake of 3H-D-asparatate by EAATs
a. To test if the neurosteroids alter the ability of different EAAT subtypes to
sequester D-[3H]-aspartate.
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b. To determine which other neurosteroids modulates the uptake of D-aspartate
by EAAT1
c. To test if PREGS affect the uptake of D-aspartate by EAAT1 in different cell
systems namely, C17.2 cells, primary astrocytes, oocytes and HEK293T cells
over-expressing EAAT1.

Specific Aim 3: To investigate the mechanism by which PREGS alter the activity of
EAAT1. The effect of the PREGS on the uptake of known substrates including Lglutamate, L-aspartate and D-aspartate will be described. Whether there are changes in
the uptake kinetic parameters (such as Km and Vmax) of these substrates will also be
evaluated.

Specific Aim 4: To determine the effect of PREGS on the ability of other EAAT1
ligands (both alternative substrates and non-substrates) to inhibit the uptake of Daspartate and L-glutamate. Endogenous, as well as non-endogenous substrates and
ligands of EAAT1 will be exploited.
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Chapter 2: Methods and Materials
Molecular Modeling:
Computational work was performed on Silicon Graphics, Inc. (SGI) Octane workstations
with R12,000 processors coupled to an SGI Origin 2000 server. The software application
suite Sybyl (versions 6.8-7.3), with the Advanced Computation module (Tripos; St.
Loius, MO), was used in adjunct with the industrially derived stochastic random search
algorithm AESOP (Masek, 1998). In later versions of Sybyl (7.0 and up), Tripos
dynamics was used instead of AESOP. Molecular databases were prepared in Sybyl
formats. Data extracted from the molecular spreadsheets were occasionally exported for
sorting and other manipulations in PERL and C code format that were automated.
Inspections of conformations and Multifit superpositions were performed in Sybyl
stereoview with CrystalEyes viewers.

The pharmacophore models were constructed as steric-strain, gas-phase derived
compositions employing established comprehensive conformational analysis methods
(Oprea et al., 1995; Marshall, 1995) with four EAAT2 inhibitor training set ligands, i.e.
L-anti-endo-3,4-methanopyrrolidine-3,4-dicarboxylate (MPDC), cis-5-methyl-L-trans2,3-PDC (PDC), (2S,3R,4S)-2-(carboxy-cyclopropyl)glycine (CCG-IV) , and L-β-threobenzyloxy-aspartate (L-β-TBOA).

Conformational space of the EAAT inhibitors in the training and test sets was
comprehensively searched employing two computational protocols: random search
(Tripos Sybyl) and the stochastic technique AESOP (Masek, 1998). Because of the
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random changes, these methods are able to access completely different region of the
conformational space from one iteration step to the next i.e., it allows ‘jumps’ into highenergy region of the molecular hyperspace. This ensures a broad sampling of the
conformational space. The random search procedure locates energy minima by randomly
adjusting the selected bonds and minimizing the energy of the resulting geometry. Chiral
centers, ring closure distances, and energy ranges were checked for consistency. This
comparison was based on an RMS match between non-hydrogen atoms in the previously
found conformers and the current conformer. At least two searches were performed on
each training set ligand and other test cases. Data from the Sybyl random searches was
deposited into a molecular database. AESOP (An Energy and Structure Optimization
Protocol) and Tripos dynamics are alternative stochastic derived programs used to search
conformational space. They apply high temperature to the molecule (which results in the
molecule being torqued and tensed), and were set to capture a conformer snapshot every
5 femtoseconds. As the temperature falls, states of lower energy become more probable
according to the Boltzmann distribution. Temperatures and times were set between 16001800 0K and 60-80K femtoseconds. Data from the AESOP and dynamics spreadsheets
were deposited into the databases established earlier. Subsequently, all conformers from
both search protocols were minimized to zero energy change defining their nearest
energy well profile. Conformer database entries were sorted as a function of conformer
total energy and cases of degenerate energy profiles were crosschecked as plausible
duplicates, based on select distances and angles defined in an exported Molfile
spreadsheet. Duplicate or nearly identical conformers (e.g., some non-essential rotamers
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for L-β-TBOA) were eliminated. Some conformations would not have been found if only
one conformer search routine had been used.

An extended closed form analysis method, which used the conformational data, was
developed to select one conformer of each of the four ligands to form the 3D
superposition models. To compare one conformation of one ligand to all conformations
of each of the remaining three training set ligands, an all-combination comparison
regimen was used by forming conformational comparison groups (shown as double
headed arrows in Figure 2.1). For each comparison group, six distinct measures were
assessed between each ligand conformer, thus permitting an assessment of molecular
similarity. These six measures included the three distances and three angles between the
proximal carboxylate carbon, C1; amino nitrogen, N and distal carboxylate carbon, C2
common to each training set ligand. Thus, the molecular spreadsheets included 3 angles
and 3 distances, along with the energy (in kcal/mol), for each conformer per training set
ligand. Additional molecular spreadsheets were also constructed in which i) the ether
oxygen of L-β-TBOA and ii) the cyclopropyl centroid of L-CCG-IV were substituted for
point C2 to consider alterative relative alignments. The resulting 3.4 X 106
conformational comparison groups were analyzed for 3D molecular similarity using a
relative difference scoring function (Figure 2.1), defined as a sum of the average of the
four conformations (as per the all-combination regime and denoted as nconformers) using
absolute value relative difference measurements (nmeasures). Averaging precluded the use
of weighting factors.
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Figure 2.1. Computational paradigm used to generate the EAAT2 pharmacophore model.
Training set ligands: MPDC, PDC, CCG-IV, and TBOA
>2 Sybyl random searches
2000 iterations

>2 AESOP stochastic search
60-80 K fsec, 1600-1800˚ K

Conformers: merge, eliminate duplicates, set to zero energy change
Spreadsheet databases established for each ligand

Compare each comformer of 4 ligand data sets to each other.
Measurements were assessed using the summed relative
difference Equation 1 to generate a scoring function for each
comparison of the alignment scenario under study. Four
alignment scenarios tested.
nconfs

MPDC

6

PDC

6
6

6
6

CCG-III

6

TBOA

!
i=1

nvar

!

!|Vx - Vy|____

i=1 (Vx + Vy) / 2

Eqn 1

nvar

nconfs

Plot scoring function values from Eqn.1 for each ligand
and select low scoring group = same points in 3D space
Repeat process for other
alignment scenarios
1 cal spring constant multi-fit overlay analysis
Select final conformer of each of the four ligands

Final multi-fit
overlay models

For Eqn 1: V are 6 variable measures ( 3 distances and 3 angles) as compared for ligand x
vs. ligand y; nvar = 6 (measures); nconfs = 6 as per comparison regime (double headed
arrows).
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The relative difference comparison measures between the conformers in a group (double
headed arrows, Figure 2.1) included three distance and three angle values. The six
conformer-to-conformer measurements were extracted from the molecular database
spreadsheets and the calculations of the scoring functions were made. Conformer
energies were not used in these calculations, thus making the scoring function energy
independent. The comparison group that had a low scoring function value (least amount
of differences amongst the six variable conformer measures in 3D space) was identified.
Thus, the lower the score the more similar the conformers are to one another,
representing molecular similarity of their space groupings. The selected ligand
conformer set was brought together with a 1 cal spring constant, and the superposition
models were appraised in stereoview using CrystalEyes viewers. The predictability
quality of the model was assessed using a leave-one-out protocol (Marshall, 1995). The
molecular spreadsheets containing all the conformers of test set ligand were exported into
MS Excel spreadsheet and the similarity calculated using equation 1.

Modulation of EAATs by neuroactive steroids:
Materials: General cell culture supplies were purchased from Becton Dickinson
(Franklin Lakes, NJ), Corning (Corning, NY), and Life Technologies (Grand Island,
NY). D-[3H]-Aspartic acid, L-[3H]-glutamic acid and L-[3H]-aspartic acid were
purchased from Dupont NEN (Boston, MA). D,L-β-threo-Benzyloxy-aspartate was
obtained from Tocris (Ballwin, MO). The steroids were purchased from Steraloids
(Newport, RI). Remaining chemicals were obtained from Sigma (St. Louis, MO).
FuGene 6 was purchased from Roche (Indianapolis, IN).
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EAAT expression and cell culture: The glutamate transporter constructs for hEAAT1,
hEAAT2 and hEAAT3 have been prepared and characterized by the other members of
our lab previously (Esslinger et al., 2005). Briefly, EAAT1, and EAAT3 cDNA were
PCR amplified from pBlueScript hEAAT1 and pBlueScript-hEAAT3 (provided by Dr M.
Kavanaugh) using primer pairs (forward:
5´ATAAGGATCCATGACTAAAAGCAACGGA3´ and reverse:
5´TATTGATATCCTACATCTTGGTTTCACT3´) and (forward:
5´ATAAGGATCCATGGGGAAACCGGCGAGG3´ and reverse:
5´TATTGATATCCTAGAACTGTGAGGTCTG3´) respectively. Each primer pair
introduced BamHI sites at the 5´ ends and EcoRV sites at the 3´ ends of each amplified
fragment. The PCR fragments were then subcloned into the BamHI and EcoRV sites
within the polylinker of the AAV vector pAM-CAG-WPRE (kindly provided by Dr
Mathew During, University of Auckland, NZ) to create pAM-CAG-EAAT1-WPRE and
pAM-CAG-EAAT3-WPRE. Final clones were confirmed by double stranded sequencing.
A 1.9 kb EcoRI fragment containing the hEAAT2 cDNA clone was subcloned from
pBlueScript-hEAAT2 (Dr M. Kavanaugh) into the EcoRI site of pAM-CAG-WPRE by
standard molecular biology techniques to create pAM-CAG-EAAT2-WPRE. C17.2 cells
(obtained from Dr Evan Snyder, Burnham Inst., La Jolla, CA) and HEK293T cells
between passages 10 and 20 were seeded at 7×104 to 1×105 cells/well and 1.5×105 to
2×105 respectively in 12-well plates and grown in complete DMEM supplemented with
10% fetal bovine serum, 1mM sodium pyruvate, 0.1mM nonessential amino acids
solution, and 0.05% penicillin / streptomycin (5000 units/ml) and gentamicin sulfate
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(0.05 mg/ml). At 24 h after plating, cells were transfected using FuGene 6 or
Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA) in a ratio of 4 ml of
Fugene 6 / Lipofectamine 2000 to 3 mg of purified plasmid DNA in accordance with the
manufacturer’s instructions. After 24 h, the relative levels of functional D-[3H]-aspartate,
L-[3H]-glutamate or L-[3H]-aspartate uptake were determined by the method of Martin
and Shain (1979) as described below.

Primary astrocytes from rat cerebral cortex were prepared by following the protocol
described by McCarthy et al (McCarthy, 1980). In brief, 2- to 4- day-old rat pups were
decapitated and the cortices isolated in Ca2+-Mg2+-free buffer (CMF). CMF (in mM):
HEPES 20, NaHCO3 4.2, Na+ pyruvate 1, 1X HBSS and bovine serum albumin
(3mg/ml). After gentle triturition, the dissociated cells were stored in DMEM/F12
medium supplemented with 15% FCS, 10mM HEPES, 14.28mM NaHCO3, 0.5mM Na
pyruvate, 0.05% penicillin / streptomycin (5000 units/ml) and gentamicin sulfate (0.05
mg/ml). After 24 hours, the media was changed to DMEM/F12 + 10% FCS. The cells in
flasks were shaken for 24hrs on day 8 at 275rpm at 370C. Between days 11 and 15, the
near-confluent cells were plated at a density of 3×104 to 5 × 104 cells/ well in 12-well
plates.

Capped cRNA was transcribed from the human brain glutamate transporter EAAT1
cDNAs by Dr. Kavanaugh’s lab as described (Arriza et al., 1994). Transcripts were
microinjected into Xenopus oocytes (50ng per oocyte) and uptake assay done 3-6 days
later.
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Transporter activity in C17.2 cells, HEK293T cells, primary astrocytes and oocytes:
Transfected C17.2 and HEK293T cells in DMEM and primary astrocytes in DMEM/F12
containing 10% FCS were grown in a humid atmosphere of 5% CO2. Near-confluent
cells were rinsed with a physiological buffer (138 mM NaCl, 11 mM D-glucose, 5.3 mM
KCl, 0.4 mM KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM
HEPES, pH 7.4) and allowed to preincubate at 370 C for 5 minutes. Uptake was initiated
by replacing the pre-incubation buffer with buffer containing D-[3H]aspartate and
inhibitors. Following a 5 minute incubation, the media was removed by rapid suction and
the cells rinsed three times with ice-cold buffer. The cells were dissolved in 0.4 N NaOH
for 24 h and analyzed for radioactivity by LSC and protein by the BCA (Pierce) method.
Transport rates were corrected for background, i.e., radiolabel accumulation at 40 C.
Initial studies confirmed that uptake quantified in this manner was linear with time and
protein levels and that uptake in untransfected C17.2 cells was indistinguishable from
background.

Uptake was measured in control (uninjected) oocytes and in oocytes expressing EAAT1
during a 10-min incubation in ND-96 buffer (96mM NaCl, 2mM KCL, 1.8mM CaCl2,
1mM MgCl2, 5mM HEPES pH 7.4) containing D-[3H]-aspartate and 10µM unlabeled Daspartate. Uptake was terminated by three rapid washes in ice-cold buffer followed by
lysis in 0.1% SDS and scintillation counting.

Curve fitting and statistical analysis: Kinetic analyses of the substrates in different
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conditions were carried out using Kaleidagraph 3.6 (Synergy Software) by non-linear
curve-fitting to Michelis-Menton equation. EC50 values for the dose-response curves
were generated using a four-parameter Hill function using equation: y = a +
b*c/(d∧c+x∧c), where a = y min, b = range of transition (y max – y min), c = slope, d =
EC50. When two groups were compared, a Student’s t test was used to compare the
values. Multiple groups were compared by ANOVA with post hoc analysis. A p < 0.05
was considered significant.
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Chapter 3: Development and Validation of EAAT2 Binding-Site Pharmacophore
Model
Introduction:
Glutamate is the major excitatory amino acid neurotransmitter in the mammalian CNS
and is essential for normal functioning of the brain (Hollmann and Heinemann, 1994). A
disruption in the control of glutamate homeostasis can lead to excitotoxicity (Olney,
1990; Doble, 1999). Five glutamate transporter subtypes, EAAT1-5, have been
discovered that are responsible for maintaining optimal extracellular concentrations of
glutamate (Danbolt, 2001; Robinson, 1999; Kanai and Hediger, 2003). However, the
specific role that each individual EAAT subtype plays to maintain glutamate homeostasis
is still being explored. One strategy to address this issue is through the development of
subtype selective inhibitors.

The flexibility in the structures of both the ligands and the binding site of the target
protein accounts for the ability of disparate ligands to bind to different subtypes of
transporters that share a common substrate. Identifying chemical ligands that
preferentially interact with particular EAAT subtype can provide insights into structural
differences between transporters. Additionally, those substrates and inhibitors that exhibit
little or no cross-reactivity with ionotropic or metabotropic glutamate receptors can be
utilized as functional probes in physiological preparations.

EAAT PHARMACOLOGY:
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The constant search for potent and selective EAAT inhibitors has led to the discovery of
several different chemical classes of compounds (Bridges et al., 1999; Dunlop and
Butera, 2006; Mennini et al., 2003). The analogues can be divided between those that are
transported across the membrane (i.e., alternative substrates) and non-transportable
inhibitors that bind the transporter without being translocated. Based upon chemical
similarity and competitive mechanism of inhibition, these molecules are hypothesized to
interact with the same general binding site on the glutamate transporters. EAAT
inhibitors can be broadly divided into several chemical classes on the basis of their
differential effects on the glutamate transporters. Apart from making direct changes to the
functional groups of the parent compounds, a wide variety of analogues have been
generated via modifications of the carbon backbone of the parent molecule. These
alterations could be achieved by either the introduction of certain chemical groups to the
carbon backbone or restricting the positions that the functional groups can assume in
three dimensional (3D) space by introducing a ring system. The successful
implementation of these strategies has lead to the development of an array of compounds
that are not only better inhibitors in terms of potency but also have properties that may be
used to probe the unique characteristics within the binding sites of different EAAT
subtypes.

β-Substituted aspartate derivatives: One of the earliest competitive inhibitors identified
(Balcar and Johnston, 1972; Robinson et al., 1993), DL-β-threo-hydroxyaspartate (βTHA) (Figure 3.1) has been shown to bind all EAAT subtypes with substrate-like activity
at EAAT1-4 (Lebrun et al., 1997) and non-transportable inhibitor-like properties at
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EAAT5 (Arriza et al., 1997). Initial studies have characterized a series of derivatives in
which the β-hydroxyl group was esterified to yield threo-β-acetoxy (TAcOAsp),
propionyloxy (TPnOAsp), benzoyloxy (TBzOAsp), (1-naphthoyl)oxy (T1NpOAsp) and
(2-naphthoyl)oxy (T2NpOAsp) THA analogues (Lebrun et al., 1997).
Electrophysiologically, TAcOAsp and TPnOAsp were found to elicit substrate-induced
currents in EAAT1-expressing oocytes with Km values of 40µM and 64µM respectively.
On the other hand, TBzOAsp and T1NpOAsp were shown to be non-transportable
inhibitor with the Ki values of about 17µM and 52µM respectively at blocking Lglutamate-induced currents in oocytes expressing EAAT1.

More recently, further modifications of β-THA have led to development of some of the
most potent, non-tranportable inhibitors available for the glutamate transporters
(Shimamoto et al., 1998; Shimamoto et al., 2004). The most prominent analogues of this
class are L-β-threo-benzyloxy aspartate (L-β-TBOA) (Shimamoto et al., 1998) and
(2S,3S)-3-(3-[4-(trifluoromethyl)benzoylamino]benzyloxy)aspartate (TFB-TBOA)
(Shimamoto et al., 2004). L-β-TBOA was found to be potent inhibitor of both EAAT1
and 2 expressed in COS-1 cells and oocytes. The Ki values for this non-transportable
inhibitor were found to be about 0.12µM and 9µM in oocytes expressing EAAT2 and
EAAT1 respectively. Moreover, L-β-TBOA did not inhibit radiolabel binding at
ionotropic and metabotropic glutamate receptors. Recently, this group has synthesized
another very potent β-THA analogue, TFB-TBOA that exhibited IC50 values for EAAT13 in the nanomolar range when tested for the inhibition of L-[14C]-glutamate uptake in
COS-1 cells expressing individual EAAT subtypes (Shimamoto et al., 2004). It showed
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Figure 3.1. β-Substituted aspartate derivatives.
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an ~15-fold preference for EAAT1 and EAAT2 over EAAT3. In the same study, TFBTBOA elicited no cross-reactivity with ionotropic glutamate receptors as determined by
the radioligand binding assay on synaptic membranes or with metabotropic glutamate
receptors when tested in transfected CHO cells.

Based on the properties of L-β-TBOA, the Esslinger group replaced the benzyloxy group
with the benzyl group yielding L-β-threo-benzylaspartate (L-β-TBA). Significantly, this
analogue is among the first compounds to show ~10-fold preference for EAAT3 over
EAAT1 and EAAT2 when tested in C17.2 cells and in oocytes (Esslinger et al., 2005). Lβ-TBA was found to be a competitive non-tranportable inhibitor with Ki values of
10.2µM, 11.4µM and 1.2µM at EAAT1,2 and 3 respectively in oocytes. With both the βbenzyl- and the β-benzyloxy- analogues, the threo- stereoisomer was found to be
significantly more potent than the erythro- form (Esslinger et al., 2005), (Shimamoto et
al., 2000). Taken together, these results suggest that the addition of bulky substituents to
the β-carbon, convert a substrate to a non-transportable inhibitor. It has been suggested
that these groups likely exhibit greater inhibitory activity because of their ability to
participate in the hydrophobic interactions within the binding site of the glutamate
transporters (Esslinger et al., 2005; Dunlop et al., 2005).

3- and 4-Substituted glutamate derivatives: Similar to the substituted aspartate
analogues, additions to the carbon backbone of glutamate have produced a series of
important analogues (Figure 3.2). Methyl substitution at C-3 of glutamate converts it to a
molecule that shows differential effects at EAAT subtypes (Vandenberg et al., 1997;
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Eliasof et al., 2001). The studies on EAAT1-4 expressed in oocytes and MDCK cells
revealed that threo-3-methylglutamate (T3MG) is a potent and competitive blocker of
glutamate transport by EAAT2 and EAAT4, but only a weak inhibitor of EAAT1 and
EAAT3 (Eliasof et al., 2001). Whereas, T3MG appears to be a non-transportable
inhibitor of EAAT2 (Vandenberg et al., 1997; Eliasof et al., 2001), it interacts with the
EAAT4 with substrate-like activity (Eliasof et al., 2001). The IC50 values for EAAT2 and
EAAT4 were reported to be 90µM and 109µM respectively in oocytes (Eliasof et al.,
2001). T3MG also elicited weak NMDA agonist activity. The erythro-3-methylglutamate
(E3MG) was shown to be inactive at EAAT1 and 2 when tested in oocytes (Vandenberg
et al., 1997).

Additionally, a number of studies have been done to characterize the effects of
substitutions at C-4 of glutamate. Both, threo- and erythro- isomers of 4hydroxyglutamate (4HG) have been demonstrated to retain the substrate activity at
EAAT1 and EAAT2 when tested in oocytes (Vandenberg et al., 1997). However, the Lthreo- isomer of 4HG was found to be much more potent (Km of 61µM and 48µM at
EAAT1 and 2 respectively) than the erythro- form (Km ~1mM at EAAT1 and EAAT2).
4-Methyl substitution of glutamate also yields molecules with differential activities
(Vandenberg et al., 1997; Alaux et al., 2005). When studied in oocytes (2S, 4R)-4Methylglutamate ((2S, 4R)-4MG) was found to exhibit substrate properties at EAAT1
with Km of 54µM and Imax of 80% relative to glutamate. However, it acts as a nontransportable inhibitor of EAAT2 and EAAT3 (Alaux et al., 2005). Interestingly,
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Figure 3.2. 3- and 4-Substituted glutamate derivatives.
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extending the 4-substitution of glutamate from methyl to higher alkyl or benzyl group
retains inhibitory activity, but converts them to non-transportable inhibitors at EAAT1, 2
and 3 as characterized in FLIPR-based membrane potential (FMP) assay (Alaux et al.,
2005). In terms of cross-reactivity, 2S,4R-4MG shows potent agonist ability at kainate
receptors and inhibits 3H-kainate binding to membranes prepared from CNS tissue (Gu et
al., 1995; Brauner-Osborne et al., 1997). While it was shown to inhibit the binding of 3HCPP to NMDA receptors, it exhibited no activity at AMPA receptors.

2-(Carboxycyclopropyl)- and 2-(carboxybutyl)- glycine analogues: These constrained
analogues lock the β- and γ- positions of glutamate by introducing a ring into the
structure, thereby limiting the number of conformations it can attain (Figure 3.3). The
availability of these probes has proven to be beneficial for developing pharmacophores
for glutamate transporters. Among the L-2-(2-carboxycyclopropyl)glycines (CCGs), the
analogues: L-CCG-III (2S,3S,4R isomer) and L-CCG-IV (2S,3R,4S isomer), have proven
to be particularly important. L-CCG-III has been reported to be the most potent analogue
in terms of its activity at glutamate carriers. It was demonstrated to be a potent
competitive inhibitor of L-[3H]-glutamate uptake in COS-1 cells expressing EAAT2 with
IC50 values of 0.29µM (Yamashita et al., 1995). When studied for its activity at inhibiting
L-[14C]-glutamate uptake in COS-1 cells, the Ki values for L-CCG-III were reported to be
7.5µM and 2.5µM for EAAT1 and EAAT2 respectively (Shimamoto et al., 1998). In
another study, L-CCG-III was reported to be effective at blocking L-[3H]-glutamate
uptake in C6 glioma cells, which expresses EAAT3 but not EAAT1 or EAAT2 (Palos et
al., 1996), and EAAT3 expressing oocytes with reported Ki values of 10µM and 13µM
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Figure 3.3. 2-(Carboxycyclopropyl)- and 2-(carboxybutyl)- glycine analogues.
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respectively (Dowd et al., 1996). Although not quiet as potent, L-CCG-IV was shown to
inhibit the EAAT2-mediated L-[3H]-glutamate uptake in COS-1 cells with an IC50 value
of 1.1µM (Yamashita et al., 1995). However, when another study tested L-CCG-IV in
COS-1 cells, it exhibited competitive inhibitor activity of L-[14C]-glutamate uptake with
IC50 values of 900µM and 673µM for EAAT1 and EAAT2 respectively (Shimamoto et
al., 1998). Similarly, L-CCG-IV was reported to competitively block the L-[3H]glutamate uptake in oocytes with Ki value of 171µM at EAAT3 (Dowd et al., 1996). Both
L-CCG-III and L-CCG-IV have been shown to bind ionotropic glutamate receptors.
While L-CCG-III was shown to inhibit the binding of [3H]-kainate in forebrain synaptic
membranes, it exhibited no activity at NMDA or AMPA receptors (Kawai et al., 1992).
L-CCG-IV was reported to have potent depolarizing ability mediated primarily through
interaction with NMDA receptors in isolated rat spinal cord (Shinozaki et al., 1989).
Additionally, L-CCG-IV also inhibited the binding of [3H]-CPP, [3H]-kainate and [3H]AMPA to synaptic membranes of the rat brain (Kawai et al., 1992).

Four stereoisomers of L-2-(2-carboxycyclobutyl)glycine (L-CBG): L-CBG-I
(2S,1´S,2´S), L-CBG-II (2S,1´R,2´R), L-CBG-III (2S,1´S,2´R), and L-CBG-IV
(2S,1´R,2´S), have been characterized in HEK293 cells transfected with EAAT1, 2 and 3
by FLIPR membrane potential (FMP) assay (Faure et al., 2006). L-CBG-I and L-CBG-III
appeared to be weak substrate and non-transportable inhibitors respectively at EAAT1, 2
and 3. L-CBG-II showed differential activities at these transporters. While shown to act
as a substrate at EAAT1 (Km = 96µM), L-CBG-II potently inhibited the uptake of Lglutamate by EAAT2 and EAAT3 with Ki values of 22µM and 49µM respectively. In the
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same study, L-CBG-IV was found to be a weak inhibitor at EAAT1 (Ki 200µM), but a
moderately potent inhibitor at EAAT2 and EAAT3 (Ki 6.6µM and 10 µM).

Pyrrolidine dicarboxylate (PDC) derivatives: This class represents compounds that are
constrained analogues of aspartate or glutamate molecules (Figure 3.4). Introduction of
pyrrolidine heterocycle limits the number of conformations that the compounds can
assume, and has proven to be important in the development of transporter
pharmacophores.

Initial studies have recognized kainate and dihydrokainate to be non-transportable
inhibitors of glutamate transport (Johnston et al., 1979; Bridges et al., 1999). Whereas,
kainate is a proven agonist at KA receptors, its modification to DHK was shown to
markedly reduce binding to KA and AMPA receptors while enhancing the uptake
inhibitor activity. The isopropyl side chain of DHK appears to be an important
determinant of its activity. 2-Carboxy-3-pyrrolidineacetate, in which the isopropyl group
is absent, is a poor inhibitor of glutamate transport with enhanced binding capacity to
KA, AMPA and NMDA receptors (Sonnenberg et al., 1996). Later, DHK was shown to
be an extremely valuable ligand, as it selectively inhibits EAAT2, the most prevalent
glutamate transporter in the brain (Arriza et al., 1997; Arriza et al., 1994; Fairman, 1995;
Shimamoto et al., 1998; Vandenberg et al., 1997). 2,4-Pyrrolidine dicarboxylates
represent constrained glutamate analogues. L-trans-2,4-PDC (2,4-PDC) has been shown
to be the most potent isomer with respect to the inhibition of glutamate uptake (Garlin et
al., 1995; Koch et al., 1999; Dowd et al., 1996; Griffiths et al., 1994) with reported Km
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Figure 3.4. Pyrrolidine dicarboxylate (PDC) derivatives.
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values comparable to that of glutamate at EAAT1 (28µM), EAAT2 (7µM), EAAT3
(27µM) and EAAT4 (2.6µM) in oocytes (Arriza et al., 1994; Fairman, 1995). While it
acts as a substrate at EAAT1-4, L-2,4-PDC was shown to be non-transportable inhibitor
of EAAT5 when expressed in oocytes (Arriza et al., 1997). As regards cross-reactivity
with glutamate receptors, L-2,4-PDC did not show binding to ionotropic EAA receptors
in radioligand binding assay (Bridges et al., 1991). However, some cross-reactivity with
metabotropic receptors has been reported in cultured astrocytes (Miller et al., 1994).
More recent studies have evaluated the effects of modifications on L-2,4-PDC. Addition
of a methyl group to form 2S,4R-4-methyl-PDC was shown to convert a substrate into a
competitive, non-transportable inhibitor of D-[3H]-aspartate uptake when tested in rat
forebrain synaptosomes (Esslinger et al., 2002). Methyl group addition can be assumed to
invoke additional interaction with the binding site or confer steric hindrance within the
molecule.

The 2,3-pyrrolidine dicarboxylates contain an embedded aspartate template. Unlike L2,4-PDC, L-trans-2,3-PDC (L-2,3-PDC) has been shown to exhibit non-transportable
inhibitor characteristics with a Ki of 23µM against D-[3H]-aspartate uptake in rat
forebrain synaptosomes (Willis et al., 1996). Significantly, while the activity of L-2,3PDC was confirmed in oocytes (Ki = 10µM), it was reported to have little or no activity
as an inhibitor at EAAT1 or EAAT3 (Bridges et al., 1999). Furthermore, the addition of a
methyl susbstituent at the 5-position of L-trans-2,3-PDC has been shown to produce
additional changes in activity at EAAT2. Whereas, the cis-5-methyl derivative retains the
inhibitor activity without compromising the potency, the trans- addition abolishes its
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activity (Willis et al., 1997). In terms of cross-reactivity, L-2,3-PDC has been shown to
be an excitotoxin and is a potent NMDA receptor agonist. The radioligand binding assays
have shown L-2,3-PDC to bind NMDA, KA and AMPA receptors in rat brain (Willis et
al., 1996).

The PDCs have further been constrained by introducing a methano-bridge between αand γ- carbons or β- and γ- carbons to yield 2 important analogues: 2,4methanopyrrolidine-2,4-dicarboxylate (2,4-MPDC) and L-anti-endo-3,4-methanopyrrolidine-3,4-dicarboxylate (L-anti-endo-3,4-MPDC). The linking of the PDC
backbone reduces the number of conformations that the molecule can assume, thus,
making it possible to identify the “preferred” conformer at the binding site. Both 2,4MPDC and L-anti-endo-3,4-MPDC were shown to be potent competitive inhibitors of D[3H]-aspartate uptake into rat forebrain synaptosomes (Esslinger et al., 1998).
Interestingly, while L-anti-endo-3,4-MPDC was identified as a potent non-transportable
competitive inhibitor, 2,4-MPDC exhibited excellent substrate characteristics with
slightly lower potency when tested in oocytes expressing EAAT2.

Taken together, the above results can help highlight key interactions within the binding
domains of individual glutamate transporter subtypes. Pharmacologically, more EAAT2preferring ligands have been identified than those exhibiting selectivity for other EAATs.
DHK and L-2,3-PDC were among the first compounds to elicit highly selective inhibitor
activity at EAAT2 (Arriza et al., 1994; Arriza et al., 1997; Fairman, 1995; Shimamoto et
al., 1998; Vandenberg et al., 1997). Although not quite as selective, compounds like L-
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anti-endo-MPDC (Esslinger et al., 1998), L-CCG-IV (Shimamoto et al., 1998; Yamashita
et al., 1995), S-2-amino-3-(3-hydroxy-1,2,5-thiadiazol-4-yl) propionic acid ((S)-TDPA)
(Brauner-Osborne et al., 2000), WAY213613 (Dunlop et al., 2005) and WAY855
(Dunlop et al., 2003) show preference for binding EAAT2 over other EAATs (Figure
3.5). In the instance of EAAT1 and EAAT3-5, only subtle distinguishing differences
have emerged. EAAT1 show substrate-like activity for compounds like L-SOS (Arriza et
al., 1994; Vandenberg et al., 1998b), (2S,4R)-4MG (Vandenberg et al., 1997) and LCBGII (L-2-(2-carboxycyclobutyl) glycine isomer) (Faure et al., 2006) and is more potently
inhibited by 1-hydroxy-1,2,3-triazol-5yl propionate (Stensbol et al., 2002). L-Cysteine
and L-aspartate-β-hydroxamate has been shown to act at EAATs and exhibit preferential
activity for EAAT3 compared to EAAT1 or EAAT2 (Zerangue and Kavanaugh, 1996b;
Roberts and Watkins, 1975). While exhibiting substrate properties at other subtypes, L2,4-PDC and THA have been shown to be non-transportable inhibitors at EAAT5 (Arriza
et al., 1997).

Insight into the requirements necessary for a molecule to act as an inhibitor can be gained
and visualized from comparing the commonalities and differences among the identified
ligands by generating a pharmacophore model (Mason et al., 2001). A pharmacophore is
the spatial mutual orientation of atom or groups of atoms assumed to be recognized by
and interact with the particular binding site. Thus, a pharmacophore specifies the spatial
relationships between the groups in 3D space. Pre-shaping the ligands to the geometry of
the binding site for mutual molecular recognition in order to minimize the loss of
conformational
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Figure 3.5. Other EAAT ligands.
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entropy upon binding and improving ligand protein interactions to obtain a favorable
(negative) enthalpy change, are important factors that can lead to the improved binding
affinity as well as reduce cross-reactivity (Velazquez-Campoy et al., 2001; D'Aquino et
al., 2000).

In this study, we have built an EAAT2-specific binding site pharmacophore model by
mapping the functional groups on the specific training set ligands and calculating the
structural similarities in 3D space (Dean and Perkins, 1998; Perkins and Dean, 1993;
Martin, 1998). This model predicts distinct regions that might influence the potency and
selectivity of the EAAT2 ligands, including: 1) a highly conserved positioning of the two
carboxylate Cs and the amino N, 2) a nearby region that can accommodate selective
modifications (e.g., cyclopropyl ring, CH3 groups, and O atoms), and 3) the region
occupied by the benzyl ring of L-TBOA. Additionally, we have incorporated a novel
EAAT3-preferring inhibitor L-β-threo-benzyl-aspartate (L-β-TBA) into our model in an
attempt to identify certain plausible differences between the interactions within the
EAAT2 and EAAT3 binding sites. Comparison of the superpositioned L-β-TBOA and Lβ-TBA in our model suggests that the selective activity at EAAT binding sites may reside
in the location and relative orientation of an aromatic ring moiety, as well as the
composition of the linking atoms attaching the aromatic ring to the aspartyl backbone of
these ligands.

Chapter 3: Results
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Four EAAT2 inhibitor training set ligands, i.e. L-anti-endo-3,4-methanopyrrolidine-3,4dicarboxylate (MPDC), cis-5-methyl-L-trans-2,3-PDC (PDC; 2S,3R,4S)-2-(carboxycyclopropyl)glycine (CCG-IV) , and β-threo-benzyloxy-aspartate (L-β-TBOA) were
selected to build an EAAT2 binding-site pharmacophore model. Each of the significant
EAAT2 inhibitor classes (Bridges et al., 1999) was carefully considered for inclusion in
the training set (Table 3.1). The major criteria were high potency, structural diversity
amongst common moieties, and relatively high selectivity. Importantly, only potent
inhibitors with little or no substrate activity were selected to afford a pharmacophore
model that may be used to define the key structural requirements for a compound to bind
to the transporter and inhibit its activity.

Most molecules can adapt more than one conformation of nearly equal energy by rotation
around single bonds. These molecular geometries correspond to the global and, in most
cases, various local minima on the multidimensional molecular energy surface (also
called potential energy surface). The conformation with the global minimum energy
seldom binds to the target protein (Nicklaus et al., 1995; Perola and Charifson, 2004).
Moreover, the “preferred” conformation depends on the interactions of the molecule with
its environment. In structure-based drug design, the so-called bioactive conformer (the
preferred conformation in the receptor-bound state) of potential drug molecules is of
special interest. The major aim of conformational analysis is to identify the preferred
conformations of a molecule under specific conditions. Therefore, conformational search
techniques (i. e., methods that locate the global and local energy minima of a structure)
play a crucial role in conformational analysis. To ensure that the bioactive conformation
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is included, a wide collection of conformations was used. Conformational space, i.e., the
total number of possible conformations a molecule can assume, was rigorously searched
using two stochastic methods (Saunders, 1987; Chang et al., 1989) e.g., random search
(Tripos) and AESOP (Masek, 1998) rather than a systematic search that examines every
possible configuration that a molecule can assume (Smellie et al., 1995b; Smellie et al.,
1995a). Separate conformational molecular databases for each training set ligand were
formed that contained all the conformers from all the searches with the duplicates and
nearly identical rotamers removed. The energy range and number of conformers for these
four ligands are shown in Table 3.2.

All conformers of all the ligands were compared to each other (combinatorial conformer
approach) based on three distances and three angles. The requirement of a minimum of
three points to overlay in three-dimensional (3D) space (Marshall, 1995) was met by
three selected points of interest (N, C1 and C2) that were shared among the ligands
(Figure 3.6). The six measures included three distances and three angles between these
points (Figure 3.1 Table). In addition to the distal carboxylate carbon of all the ligands,
the electron-rich benzyloxy ‘O’ of L-β-TBOA and the ‘centroid’ of LCCG-IV were
considered as point C2 to generate four plausible pharmacophore models.

While the proximal carboxylate carbon (C1) and amino nitrogen (N) were common in all
models the distal carboxylate carbon (C2) (Model A) was replaced by either the
benzyloxy ‘O’ of TBOA (Model B and D) or cyclopropyl ‘centroid’ of CCG-IV (Model
C and D). The comparison of the ligands was scored (Dean and Perkins, 1998) for
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Table 3.1. Criteria for the selection of training set.
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Inhibitory activity of ligands selected in the training set for the development of EAAT2
specific pharmacophore model. * IC50.

Table 3.2. Number of unique conformers and energy range for each of the ligands in the
training set.
L-anti-endo3,4-MPDC
# Conformers
Energy Range
(kcal/mol)

100
107.158-157.484

cis-5-Me-Ltrans-2,3-PDC
107
10.006-91.617

L-CCG-IV

L-β-TBOA

440
103.637-189.635

208
1.635-1116.144

Conformational space was searched using two stochastic techniques: random search and
AESOP. These unique conformers were obtained after the removal of duplicates.
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Figure 3.6. Training set with points-of-interest labeled.
Alternative C2
C2
C2

HO2C

H

H

H

CO2H

C1

HO2C

CO2H
N
H
H

H2N

N

L-anti-endo-3,4-MPDC

cis-5-Me-2,3-PDC

DISTANCE
N-C2

H

CO2H

N

C1

N-C1

H
H

CO2H H C
N
3
H
H

C2

N

CO2H
H

O
H2N

H

CO2H

C1

L-CCG-IV

L-β-TBOA

ANGLE
C1-C2

N-C1-C2 N-C2-C1

C1-N-C2

The points-of-interest: amino nitrogen (N), proximal (α) carboxylate carbon (C1) and
distal carboxylate carbon (C2), were selected that were shared among all the ligands in
the training set. For each comparison group, six distinct measures (three distances and
three angles) were defined between each ligand conformer for the assessment of
molecular similarity. Additionally, the ether oxygen of L-β-TBOA and the cyclopropyl
centroid of L-CCG-IV were substituted for point C2 to consider alternative relative
alignments.
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relative structural similarity in 3D space using Equation 1 (Figure 3.7). The selected
ligand conformer set was brought together (multifit) with a 1 cal spring constant. The
final superposition models (Figures 3.8-3.11) were selected on the basis of their scoring
function values (Charts in Figures 3.8-3.11) and visual inspection using CrystalEyes
viewers. The best superposition models exhibited low scoring function values as
expected.

Based upon the stringent alignment of the carboxylate groups, the amino moieties and the
carbon backbone, model A was selected (Figure 3.8). The other models, which were
based upon the superpositioning of the ether-O of L-β-TBOA at the C2 carboxylate
position (Model B), the centroid of the cyclopropyl ring of L-CCG-IV at the C2
carboxylate position (Model C), or both (Model D), were not considered further because
each showed inappropriate positioning of the carbon backbone and/or relevant side
chains. For instance, in models C and D, the carbon backbone markedly deviated outside
the bounds defined by the other analogues. Figure 3.12 shows model A with critical
distances and angles between the various functional groups listed in an inset along with
the graphical representation in the x-y plane. The generated model suggests some key
interactions that may contribute to their activity as well as selectivity of this group of
ligands. These include the almost planar arrangement of the α-C, β-C, amino-N and
distal carboxylate-C atoms. The identical positioning of the two carboxylate carbon
atoms among the inhibitors suggests a critical electrostatic interactions between these
groups and corresponding residues in the binding site and / or cotransported ions.
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Figure 3.7.
Equation 1.
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Equation 1: V are 6 variable measures (3 distances and 3 angle) as compared for ligand x
versus ligand y. nvar = 6 (measures); nconfs = 6 per comparison group regime (B). The
relative difference comparison measures between the conformers in a group (double
headed arrows) included three distances and three angles.
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Figure 3.8. EAAT2 binding-site pharmacophore model A.

The chart shows the distribution of different alignment groups based on the scoring
function value. Only top 200 alignment groups are shown. The alignment group # 12 was
chosen based on the visual inspection using CrystalEyes viewers. The points-of-interest
are indicated in the color-coded images. Three views of the same model are shown.
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Figure 3.9. EAAT2 binding-site pharmacophore model B.
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In model B, the distal carboxylate carbon of L-β-TBOA is substituted with the benzyloxy
oxygen as point C2 . The chart shows top 200 alignment groups. The alignment group # 6
was chosen on the basis of the assessment done using CrystalEyes viewers. The pointsof-interest are indicated in the color-coded images. Three views of the same model are
shown. The table shows the measures used for the alignment of the training set ligands.
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Figure 3.10. EAAT2 binding-site pharmacophore model C.
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In model C, the distal carboxylate carbon of L-CCG-IV is replaced by the cyclopropyl
centroid as point C2 (Table). The chart shows the distribution of different alignment
groups based on the scoring function values. The points-of-interest are indicated in the
color-coded images. Two views of the same model are shown. The table shows the
measures used for the alignment of the training set ligands.
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Figure 3.11. EAAT2 binding-site pharmacophore model D.
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In model D, the distal carboxylate carbons of L-CCG-IV and L-β-TBOA are replaced by
the cyclopropyl centroid and the benzyloxy oxygen as point C2 (Table). The chart shows
the distribution of different alignment groups based on the scoring function values. The
points-of-interest are indicated in the color-coded images. Two views of the same model
are shown. The table shows the measures used for the alignment of the training set
ligands.
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Figure 3.12. Graphical representation of EAAT2 binding-site pharmacophore model A.

N – C1
N – C2
C1 – C2
N – C1 – C2
N – C2 – C1
C1 – N – C2

Distance (Å)
2.5 ± 0.1
3.4 ± 0.2
3.4 ± 0.2
Angle
66 ± 0.4
43 ± 1.3
71 ± 1.3

This representation depicts the averaged position of structural features. The averaged
specific angle and distance measurements are reported in the table.
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Secondly, the possibility of lipophilic interaction between the phenyl ring and the
hydrophobic residues within the binding site. Additionally, positioning of the cyclopropyl
ring of L-anti-endo-3,4-MPDC suggest a possible Π bond-like interaction with the
protein.

Pharmacophore Validation: It is important that the generated pharmacophore be able to
predict the potential activity of an unknown ligand. Therefore, to check the quality of the
model, it was validated with three test ligands using a “leave-one-out protocol”
(Marshall, 1995). Three potent non-substrate inhibitors e.g., dihydrokainate (DHK;
2S,4R)-4MG and 4-Me-L-trans-2,4-PDC, were selected to generate a test set (Figure
3.7). Similar to the training set, the criteria for the selection for the test ligands were high
potency, relative selectivity, no substrate activity and structural diversity. Conformational
space searching for each test ligand was done using randomsearch, and AESOP (or
dynamics (Tripos) stochastic methods. Three more databases containing unique test set
conformers with the required angles and measures were created. All the conformations of
the test ligands were compared against the generated pharmacophore, model A (Figure
3.2) and scored for relative structural similarity using Equation 1. The low scoring
function values showed tight alignment of the test ligands against the pharmacophore
thus confirming the robustness of the model (Figures 3.13-3.15).
Our non-transportable inhibitor-based model was then used to define putative regions that
may distinguish substrates from non-substrates. Three common substrates, L-glutamate,
D- and L- aspartate (Table 3) were used in our modeling protocol to generate multifit
models as shown in Figures 3.16. As can be seen, these substrates fit extremely well with
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the pharmacophore model at low scoring function values. They appear to be virtually
indiscernible within the pharmacophore, while the non-substrate bulk seems to protrude
toward the periphery. This arrangement of excess bulk caused by the substituents, as well
as cyclic carbons, may hinder effective transport as a result of unfavorable energy
requirement to assume substrate-like conformation. Moreover, the direct interaction of
the substituents with the binding site can influence their transport activity.

Recently, Esslinger et al have synthesized an EAAT3 selective non-transportable
inhibitor L-β-benzyl aspartate (L-β-BA). L-β-BA was characterized by the other
members of our lab and by Michael Kavanaugh’s lab. L-β-BA shows approximately 10fold greater activity at EAAT3 than EAAT1 or EAAT2 in C17.2 cells and the
electrophysiological recordings revealed that it acts as a competitive inhibitor (Esslinger
et al., 2005). These findings have been summarized in Figure Table 3.4. Additionally, it
should be noted that the erythro stereoisomers of both L-β-BOA and L-β-BA have been
found to be significantly less potent than their threo counterparts (Esslinger et al., 2005;
Shimamoto et al., 2000) (Table 3.4). Secondly, whereas L-β-TBOA is relatively more
selective for EAAT2 (Shimamoto et al., 1998; Shimamoto et al., 2000), L-β-TBA is more
selective for EAAT3 (Table 3.5). This suggests that certain stereospecific interactions
may account for differences in the activities of the stereoisomers of L-β-threo-BA at
EAAT2 and EAAT3. We exploited our EAAT2 specific model in an attempt to identify
these differences. To see if any variations could be predicted between EAAT2 and
EAAT3 binding sites, we incorporated L-β-threo-BA into our model as well as the
erythro- stereoisomers of both L-β-BA and L-β-BOA. All three compounds were
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Table 3.3. Inhibitory activity of test set ligands at EAAT1, EAAT2 and EAAT3.
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TEST SET
cis-4-CH3-L-trans- Dihydrokainate
2,4-PDC
Ki (µM) Imax (%) Ki (µM) Imax (%)

2S,4R-4-MG
Ki (µM)

Imax (%)

EAAT1

14.1

21

-

-

32

71.8

EAAT2
EAAT3

1.8
16.6

0
0

9.2
0

0
0

3.1
34

0
66

# Unique
Conformers
Energy Range
(kpm)

88

528

928

8.309-13.401

10.202-25.588

1.741-13.155

Three EAAT2-preferring non-substrate inhibitors were selected in the test set. The
indicated points-of-interest (N, C1, C2) are shared by all the ligands in both the training
set and the test set. The number of unique conformers and the energy range are also
shown in the table.
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Figure 3.13. Comparison of the test set ligand, 2S,4R-4MG, with the pharmacophore
model A.

2S,4R-4MG superpositioned on the pharmacophore model A was selected based on the
low scoring function value. The points-of-interest are labeled. Two views of the same
alignment are shown. The scoring function values are shown for different alignments in
the chart.
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Figure 3.14. Comparison of the test set ligand, cis-4-methyl-L-trans-2,4-PDC, with the
pharmacophore model A.

DHK superpositioned on the pharmacophore model A. The alignment group was selected
based on the low scoring function value. The points-of-interest are labeled. Two views of
the same alignment are shown. The scoring function values are shown for different
alignments in the chart.
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Figure 3.15. Superpositioning of dihydrokainate (DHK) on the EAAT2 binding-site
pharmacophore model A.

Based on the low scoring function value, the above alignment was selected. The pointsof-interest are labeled. Notice the positioning of the isopropyl group of DHK and the
methyl group of cis-5-methyl-L-trans-2,3-PDC are oriented in the same region.

72

Figure 3.16. The superposition of L-glutamate, L-aspartate and D-aspartate with the
EAAT2 binding site pharmacophore model.

These substrates show almost identical alignment when superpositioned (1 cal spring
constant) with the model. The alignment groups are selected based on their low scoring
function values.
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subjected to same rigorous space searching using stochastic methods mentioned above.
The resultant molecular databases containing all the unique conformers were compared
to the pharmacophore to generate the similarity score using equation 1 (Figure 3.17). The
resultant multifit alignments shown in Figure 3.13 were selected on the basis of low
scoring function value and visual inspection with CrystalEyes viewer (Figure 3.18).
The similar positioning of the lipophilic phenyl ring of both L-β-TBOA and L-β-TBA
suggests lipophilic interactions within the binding sites of the transporter and that the
erythro- stereoisomers may render the phenyl rings inaccessible to this region. This
lipophilic region may be common to both EAAT2 and EAAT3. However, subtle
differences in the size, location and/or orientation of the aromatic ring with respect to the
lipophilic residues in the transporters may exist. It seems likely that the ether ‘O’ of L-βTBOA may be participating in the electrostatic interaction within the EAAT2 binding site
whereas this interaction may be substituted by a more lipophilic interaction within the
EAAT3 binding site thus contributing to the differential effects produced by L-β-TBOA
and L-β-TBA.

Chapter 3: Discussion

Taking advantage of the availability of selective ligands for EAAT2, we have built a nonsubstrate inhibitor based EAAT2-specific binding site pharmacophore model (Figure
3.8). The model was derived by calculating 3D structural similarities of multiple training
set ligands (Martin, 1998; Perkins and Dean, 1993; Dean and Perkins, 1998). The
inclusion of ligands in the training and test sets was based upon structural diversity,
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Table 3.4. Inhibitory activity of β-substituted aspartate analogues is EAAT1, EAAT2 and
EAAT3.

COMPOUND

CONC

EAAT1
H-D-Asp
Uptake
(% of Control)

EAAT2
H-D-Asp
Uptake
(% of Control)

L-Aspartate

100µM

4

16

15

D,L-β-threoBenzyloxy-Asp

100µM

5

2

9

L-β-threoBenzyl-Asp

100µM

8

9

1

L-β-erythroBenzyl-Asp

100µM

59

48

14

3

3

NH2

NH2
HOOC

HOOC

EAAT3
H-D-Asp Uptake
(% of Control)

NH2

COOH

COOH

3

COOH
HOOC
O

L-β-threo-benzyl aspartate
(L-β-TBA)

L-β-erythro-BA
(L-β-EBA)

L-β-TBOA
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Table 3.5. The inhibitory activity of L-β-TBA and L-β-TBOA at EAAT1, EAAT2 and
EAAT3.
L-β-TBA

D,L- β-TBOA

Ki (µM)

Ki (µM)

EAAT1
EAAT2
EAAT3

8.7
10.0
0.8

9
0.2
-

# Conformers
Energy Range
(KPM)

817
1.0916-437

208
1.635-1116.14

Figure 3.17. Charts showing the distribution of alignments groups for the L-β-TBA, L-βEBA and L-β-EBOA.
A. L-β-TBA
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B. L-β-EBA

C. L-β-EBOA
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Figure 3.18. Assessment of conformations and activities of L-β-TBOA, L-β-EBOA, L-βTBA and L-β-EBA against the EAAT2 binding-site pharmacophore.

The pharmacophore model is shown in (A). The superposition (1 cal spring constant) of
L-β-TBOA and L-β-TBA with the model (B) suggesting that possible points of
divergence between the EAAT2 and EAAT3 pharmacophores may include subtle
differences in the size, location and/or orientation of the aromatic ring or in the oxygen
atom present in the linking group of L-β-TBOA, but not L-β-TBA. In (C) the
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superposition of L-β-threo- and L-β-erythro-BOA with the model illustrating the better
fit of aspartyl backbone of the threo diastereomer with other aligned molecules, in
addition to the distinct placements of the ether ‘O’ and the benzyl group that might
influence the potency and selectivity for this inhibitor at EAAT2. A similar conclusion is
reached regarding L-β-TBA, when the two diastereomers of the L-β-BA are compared.
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potency and relative selectivity. Comparison of one conformer of one ligand to all the
conformers of each of the three remaining ligands in the training set was based on six
selected measures between the common functional groups, e.g., one amino and two
carboxylate groups, shared by each ligand. The lower scoring function values for
comparison groups represented the least amount of differences amongst the six variable
conformer measures in 3D space. Based upon low scoring function values and visual
appraisal in stereoview using CrystalEyes viewers, the final model was selected. The
intent of this model is to predict structural requirements for the ligand to act as substrate
or a non-substrate inhibitor, as well as identify putative points of difference between the
EAAT subtypes.

The planar arrangement of the two carboxyl groups and the amino group in 3D space
suggests that these regions may identify a critical ligand triad that defines the initial
recognition within the binding site. As was demonstrated, both the substrates and nontransportable inhibitor aligned closely on these selected points-of-interest, suggesting that
these functional groups may exhibit electrostatic interactions with the complementary
residues found within the EAAT binding site and possibly with select ions. Subsequently,
other critical ligand structural properties may influence important inhibitor behavior such
as: substrate versus non-substrate ligand activity, potency, and EAAT subtype selectivity.
Our model defines three additional regions distinct from the carboxyl and amino
functionalities within the 3D model space.
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One of these regions is occupied by the extended arm of the benzyl group of L-β-TBOA.
The presence of amino acid residues near the initial recognition binding site moieties may
offer lipophilic interaction with the benzyl group in this region. This idea is further
supported by the newly identified ligand, WAY213613 (Dunlop et al., 2005). In the
modeling studies by this group, WAY213613, was shown to project its aromatic side
chain, which occupies a much larger volume, in the same direction as the benzyl group of
L-β-TBOA. Additionally, the orientation of the benzyl group within the binding site may
play a crucial role in determining this lipophilic interaction. When the less potent erythro
stereoisomer L-β-EBOA (Shimamoto et al., 2000) was aligned with our pharmacophore
model, the two benzyl groups occupied distinct positions within the binding site with
respect to the amino acid and carboxylate triad discussed above (Figure 3.18). The
positioning of the benzyl group of L-β-TBOA suggests that this model presents an
orientation that is more favorable for complimentary interaction with the residues in the
binding domain. It is plausible that the L-β-EBOA benzyl group lipophilic interaction is
disrupted or it experiences steric hindrance or both within the binding site.

The test set ligand, DHK, has been shown to be an EAAT2-selective, non-tranportable
inhibitor (Arriza et al., 1994). When superpositioned on our pharmacophore model as a
validation step, DHK projected its isopropyl group in a distinct region. This isopropyl
group has been shown to be an important determinant for activity at glutamate
transporter, since 2-carboxy-3-pyrrolidineacetate, in which the isopropyl group is absent,
is a weaker inhibitor of glutamate transport , even though it has enhanced binding
capacity to KA, AMPA and NMDA receptors (Sonnenberg et al., 1996). The closely
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related analogue, L-trans-2,3-PDC, has also been shown to be a preferential EAAT2 nonsubstrate inhibitor (Bridges et al., 1999). The addition of a methyl susbstituent at 5position of L-trans-2,3-PDC also has important consequences on its activity. Whereas,
the cis-5-methyl addition retains the compound’s inhibitory capacity without
compromising potency, the trans- addition abolishes its activity. Interestingly, in the
superposition model, DHK projected its isopropyl side chain in the general vicinity of the
methyl group of cis-5-methyl-L-trans-2,3-PDC. This unique placement of methyl and
isopropyl groups suggests a stereospecific lipophilic interaction in this region. It remains
less clear whether this area is a distinct lipophilic pocket associated with the EAAT
protein.

Another region, that may be important, is the distinct positioning of the cyclopropyl ring
of L-anti-endo-3,4-MPDC in our model . This area may confer a Π-bond like character to
this region and that modest structural ligand changes may be tolerated within the
complementary binding area. Traditional substrates for EAATs have been mostly acyclic
and devoid of steric bulk. It appears that the modification of parent substrate either by
addition of substituents or the introduction of cyclic constraint, may hinder effective
transport as a consequence of excess bulk and / or substituent-induced ligand
conformational changes as demonstrated by 2,3-PDC and methyl glutamate analogues.
However, constraining a molecule through the incorporation of cyclic structures can lead
to both the substrate and the non-substrate inhibitors. For example, the highly restricted
bicyclic analogues of PDC, L-anti-endo-3,4-MPDC and 2,4-MPDC, have been shown to
inhibit glutamate transport in rat forebrain synaptosomes (Esslinger et al., 1998).
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However, electrophysiological studies in oocytes revealed that whereas L-anti-endo-3,4MPDC is a non-substrate inhibitor, 2,4-MPDC exhibits excellent substrate acitivity at
EAAT2 expressed in oocytes (Esslinger et al., 1998). Therefore, the obvious assumptions
regarding the ability of ligands to transport based solely upon the degree of flexibility can
be misleading.

The inclusion of substrates into our model was done to identify the plausible properties
that separate substrates from non-substrates. The general close fit of L-glutamate, L- and
D- aspartates within the pharmacophore at low scoring function values confirms its
predictive quality. The protrusion of substituents (e.g., (2S,4R)-4MG, cis-4-methyl-2,4PDC, L-β-TBOA) (Figure 3.16) as well as the cyclic rings (e.g., L-trans-2,3 PDC, DHK)
(Figures 3.15), towards the periphery may invoke additional interactions with the binding
site residues that may preclude the ability of the ligands to be effectively translocated.
Thus, enhanced hydrophobic interactions within the binding site, by addition of the
lipophilic substituents to the ligand, can increase potency while reducing the substrate
activity of the inhibitor.

The novel EAAT3-preferring inhibitor L-β-BA exhibits similar stereochemical trends as
L-β-BOA. The threo- stereoisomer of L-β-BA is significantly more potent than the
erythro form. When incorporated within our EAAT2-specific model, the benzyl group of
L-β-TBA aligned well with that of L-β-TBOA (Figure 3.18 D). As expected from the
analysis of L-β-BOA, the benzyl group of threo- and the erythro- stereoisomers of L-βBA occupy distinct regions in our model. Thus, both the EAAT2 and EAAT3 binding
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sites may be thought to accommodate the benzyl groups to various extents and offer the
lipophilic interaction with the amino acid residues conferring high potencies for
respective threo stereoisomers. What separates the EAAT subtype-specific potencies of
L-β-TBOA and L-β-TBA may be the linking of phenyl group to the aspartate backbone
and the interaction with the binding site residues within this region. Additionally,
differences in the orientation, size and location of the lipophilic groups can play
significant role in determining the selectivity of the inhibitor. The oxygen atom of L-βTBOA may be involved in electrostatic interactions like hydrogen bonding within the
EAAT2 binding site residues. It may be that the corresponding residues within the
EAAT3 binding site prefer hydrophobic rather than electrostatic interactions. Hence,
selectivity for one EAAT subtype relative to another may be driven by either favorable or
unfavorable ligand-protein residue side chain interactions involving the ligand phenyl
group and the linking region.

Recently, John Gerdes’ research group has also developed an EAAT3 homology model
using the coordinates from the crystal structure of Gltph sequence (Yernool et al., 2004).
The studies were performed at the Molecular Computational Core Facility at the
University of Montana. The investigation utilized a Linux (Redhat Enterprise 3)
workstation (dual 3.0 GHz processors, 2 GB memory) employing SYBYL 7.0 (Tripos,
Inc.; St. Louis, MO) and related Bioploymer and FlexX software suites. Submission of
the alignment to SwissModel provided the homology model. The docking studies were
subsequently done with the hEAAT3 homology model to define substrate space
coordinates. Utilizing this model, we superpositioned our EAAT2 pharmacophore on the
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defined substrate space coordinates in an attempt to compare the binding site interactions.
The positioning of the benzyl group of L-β-TBOA, as configured in our pharmacophore,
suggested a possible steric clash with the EAAT3 transmembrane domain 7 (Figure 3.19).
However, rotation of L-β-TBOA in our model by 1800, while maintaining the 3-point
consistency of the functional groups, orients its benzyl group in the general direction of
the HP2 loop. This later orientation of L-β-TBOA is more appropriate considering the
lipophilic nature of the HP2 loop. Moreover, it has been reported that the HP2 loop can
undergo a conformational change upon binding of ligands and thus, acts as an
extracellular gate (Grunewald et al., 1998; Grunewald and Kanner, 2000; Slotboom et al.,
1999; Slotboom et al., 2001; Zarbiv et al., 1998; Seal and Amara, 1998; Seal et al., 2000).

In the last few months, another set of high resolution crystal structures of EAAT bacterial
homologue GLTPH were published with either the substrate, L-aspartate, or the nontransportable inhibitor, L-β-TBOA, bound to the transporter (Boudker et al., 2007). This
provided an opportunity to compare our pharmacophore with the L-β-TBOA from the
crystal structure. The amino nitrogen, the distal and proximal carboxylate carbons, the
benzyloxy oxygen, as well as the carbon backbone matched well with each other. The six
measures (3 angle and 3 distances), as predicted from our model and the L-β-TBOA
bound in the crystal structure, were found to be almost identical.

In both instances, the benzyl groups of L-β-TBOA appears to project toward the HP2
loop. The two configurations of L-β-TBOA did, however, differed from each other only
with respect to the rotation of benzyl group about the ether oxygen atom (Figure 3.19).
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The differences are likely attributable to the fact that in our model, L-β-TBOA was
docked on the “closed” or the substrate-bound form rather than the “open” non-substrate
bound form. The results suggest that the phenyl group of L-β-TBOA seems to interact
with helical hairpin 2 (HP2) loop. The possibility of HP2 loop acting as an extracellular
gate is compelling. Boudker et al propose that the binding of two sodium ions and Laspartate causes HP2 loop to close, thereby permitting the conformational change needed
for the subsequent transport (Boudker et al., 2007). The binding of L-β-TBOA prevents
HP2 from closing, thus locking the transporter in an ‘open’ state.

Both, our pharmacophore model and the crystallographic data, suggest that the functional
groups and the carbon backbone of the substrates occupy very similar, if not identical,
regions. Thus, it is possible that subtype-selectivity and substrate activity resides in the
subtle differences in the size and orientation of the lipophilic substitutions that can be
allocated to the template. Exploiting these subtle differences among the binding sites of
EAAT subtypes using these compounds’ templates can lead to development of ligands
with highly selective binding profiles. With the development and refinement of specific
models for each subtype, design of more selective substrates and non-transportable
inhibitors is possible. Identifying and incorporating important functional domains of
novel ligands into evolving models will significantly improve our understanding of the
physiology and pathophysiology attributed to these transporters.
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Figure 3.19. Positioning of L-β-TBA docked on the binding site of EAAT3 homology
model.

A

MODIFIED
POSITION

ORIGINAL
POSITION

B

Open HP2

Closed HP2
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A. The alignment of L-β-TBA (superpositioned with the pharmacophore model) with the
defined substrate space coordinates within the EAAT3 homology model. The original
positioning of the phenyl ring of L-β-TBA (green) suggests a possible steric clash with
the EAAT3 transmembrane domain 7. However, rotation of L-β-TBA in our model by
1800 (pink), while maintaining the 3-point consistency of the functional groups, orients
its benzyl group in the general direction of the HP2 loop. B. The positioning of L-βTBOA as reported in the crystal structure by Boudker et al. 2007.
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Chapter 4: Characterization of EAAT Modulation by Neuroactive Steroids

Introduction:

Modulation of EAATs: The glutamate transporter system is highly regulated and one
that is modulated at different levels. For example at the genomic level, certain
compounds, including: β-lactam antibiotics, injury-induced growth factors, retinol and
corticosterone have been shown to alter transcription and translation of the transporters
(Rothstein et al., 2005; Tian et al., 2007; Su et al., 2003; Figiel et al., 2003; Schlüter et
al., 2002; O'Shea et al., 2006; Thorlin et al., 1998). EAATs can be also be regulated by
changes in trafficking (Gonzalez and Robinson, 2004; Hughes et al., 2004; Duan et al.,
1999). In addition, certain molecules including EAAT interacting proteins (Jackson et al.,
2001; Lin et al., 2001), zinc (Mitrovic et al., 2001) and arachidonic acid (Zerangue et al.,
1995), appear to influence their function by allosteric modulation (Vandenberg et al.,
2004). A review on the modulation of these transporters by genomic and the trafficking
mechanisms is presented in Chapter 1.

Allosteric Modulation of glutamate transporters:
Zinc: Zinc has been suggested to exhibit differential effects at the EAAT subtypes
(Mitrovic et al., 2001; Vandenberg et al., 1998a). While Zn2+ was shown to modulate the
activities of EAAT1 and EAAT4 expressed in Xenopus laevis oocytes, it appears to have
no effects on EAAT2 or EAAT3. The binding of Zn2+ ion to EAAT1 inhibited the
transport of glutamate in a non-competitive fashion. In the case of EAAT4, however,
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arachidonic acid was shown to selectively inhibit the chloride conductance, with little
effect on the transport of glutamate. The effects of zinc were found to be fully reversible
and the Zn2+-binding sites have been identified in the glutamate transporters using sitedirected mutagenesis (Mitrovic et al., 2001; Vandenberg et al., 1998a).

Polyunsaturated fatty acids (PUFAs): Another small molecule, arachidonic acid, has
been shown to differentially modulate the activities of EAAT1, EAAT2 (Zerangue et al.,
1995) and EAAT4 (Fairman et al., 1998; Tzingounis et al., 1998; Poulsen and
Vandenberg, 2001). While arachidonic acid, at micromolar concentrations, inhibited the
EAAT1-mediated glutamate uptake by reducing the maximal transport rate by about
30%, it increased the apparent affinity of glutamate for EAAT2 more than 2-fold when
expressed in oocytes and HEK293 cells (Zerangue et al., 1995). In a similar vein,
arachidonic acid was reported to reduce Vmax for glutamate uptake in salamander Müller
cells, which expresses EAAT1 as the major transporter, by affecting membrane
characteristics (Barbour et al., 1989). However, arachidonic acid was also reported to
non-competitively inhibit EAAT2 (GLT1) in reconstituted system in which the purified
transporter was incorporated into liposomes (Trotti et al., 1995). Taken together, these
results suggest that the effects of arachidonic acid may be dependent upon the cell-type in
which the transporter is expressed, and/or the make-up of lipids surrounding it.

Studies on EAAT4 concluded that while there is no change in the uptake of glutamate in
the presence of arachidonic acid, it was found to activate an uncoupled proton current
associated with glutamate-bound EAAT4 (Fairman et al., 1998; Tzingounis et al., 1998;
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Poulsen and Vandenberg, 2001). This effect was attributed to the binding of arachidonic
acid directly to EAAT4. Additionally, the cyclo-oxygenase inhibitor, niflumic acid
(Poulsen and Vandenberg, 2001) and other polyunsaturated fatty acids (PUFAs), e.g.,
docosahexaenoic acid (DHA) and linolenic acid (Fairman et al., 1998) resulted in similar
activation of this proton current. In addition to the effects produced by simultaneous
application, these compounds have the ability to differentially alter glutamate transport
following longer times of exposure (Berry et al., 2005). For example, preincubation with
DHA for 10-40 minutes was reported to modulate the activities GLT-1, GLAST and
EAAC1 via different mechanisms in HEK cells. In the instance of GLT-1 and EAAC1,
DHA (100-200µM) appears to stimulate D-[3H]aspartate uptake ~72% and 45%
respectively via a mechanism requiring extracellular Ca2+ and involving CaM Kinase II
and PKC, but not PKA. In contrast, the inhibitory effect (~40%) on GLAST does not
require extracellular Ca2+ and does not involve CaM kinase II, PKC or PKA (Berry et al.,
2005).

The differential regulation of EAATs supports the concept that the subtypes may play
important individual roles in controlling extracellular glutamate concentrations needed
for signaling. In the present work, we have identified and characterized a potentially
novel site at which the EAATs may be differentially regulated. The compounds that were
used to characterize this site were neuroactive steroids, including pregnenolone sulfate
(PREGS).
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Neuroactive Steroids: The nervous system is a target for two different pools of steroids,
one coming from the peripheral glands (i.e., steroid hormones) and the second one
originating directly in the nervous system (i.e., neurosteroids) (Agis-Balboa et al., 2006;
Koenig et al., 1995; Plassart-Schiess and Baulieu, 2001). Central and peripheral nervous
systems have inherent enzymatic capacity to synthesize various neurosteroids from
cholesterol or other steroidal precursors (Baulieu, 1998; Corpechot et al., 1981;
Corpechot et al., 1983; Corpechot et al., 1993; Liere et al., 2000). Furthermore, certain
steroids remain in the nervous system long after adrenalectomy or gonadectomy
(orchidectomy) (Corpechot et al., 1981; Corpechot et al., 1983; Corpechot et al., 1993;
Liere et al., 2000). “Neuroactive steroids” is the general term that encompasses all the
steroids present in the brain. They may be derived by in situ synthesis, obtained from the
peripheral hormones, or converted by enzymatic activation in metabolites which are more
active and in some cases utilize a different mechanism of action (Melcangi and Panzica,
2006; Paul and Purdy, 1992) [Paul et al 1992; Melcangi et al 2006].

Neurosteroids are synthesized from cholesterol by a series of enzymatic reactions
mediated both by P450 and non-P450 enzymes (Mellon and Griffin, 2002; Mellon et al.,
2001; Robel and Baulieu, 1995). The biosynthesis of steroids and neurosteroids requires
the movement of cholesterol from the outer to the inner mitochondrial membranes where
cholesterol side-chain cleavage enzyme, cytochrome P450scc (CYP11A1), resides and
converts cholesterol into pregnenolone, the precursor to other neurosteroids (Mellon and
Griffin, 2002; Mellon et al., 2001). This dynamic process is modulated by both the
control of the intrinsic enzymatic activity of P450scc and by substrate availability. For
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this reason, cholesterol transport within the mitochondrion has emerged as the key
regulation point for steroidogenesis. Peripheral-type benzodiazepine receptor (PBR),
along with steroidogenic acute regulatory protein (StAR), facilitates the efficient
production of steroid hormones by regulating the translocation of cholesterol across the
mitochondrial membranes (Jefcoate, 2002; Papadopoulos, 2004; Papadopoulos et al.,
1997). The brain contains additional steroid metabolizing enzymes, including
sulfonyltransferases and sulfohydroxylases, which convert classic hormones to a variety
of sulfated neuroactive compounds. To maintain and regulate the effects of neuroactive
steroids, the steroidogenic enzymes in the CNS and PNS are regulated during
development. Moreover, their regulation is region and cell-specific.

Neuroactive steroids exert their effects on the brain either through activation of
intracellular steroid receptors (genomic pathway) or via non-genomic route (McEwen,
1994; Plassart-Schiess and Baulieu, 2001). The genomic effects are characterized by a
delayed onset and prolonged in duration, while non-genomic effects are typically rapid in
onset and shorter in duration (McEwen, 1994).

Genomic Effects: Steroid hormones that are synthesized in the periphery can cross the
blood-brain barrier, and can function at the genomic level to produce changes in mood
and behavior. These effects develop relatively slowly (over minutes to hours), and can
persist long after the disappearance of the steroid from the brain (McEwen, 1991c;
McEwen, 1994).
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These effects are mediated by the receptors distributed throughout the brain that are
present on both neurons and glia (McEwen, 1991c; McEwen et al., 1986) (McEwen et al.,
1986; McEwen, 1991a; McEwen et al., 1983; O'Keefe and Handa, 1990). The steroid
hormone receptor superfamily consists of a large number of genes. It includes receptors
for the steroids, estrogen (ER), progesterone (PR), glucocorticoid (GR),
mineralocorticoid (MR), and androgen (AR) as well as the receptors for thyroid hormone
(TR), vitamin D (VDR), retinoic acid (RAR), and 9-cis retinoic acid (RXR), and
ecdysone (EcR) (Tsai and O'Malley, 1994; Evans, 1988). This superfamily is
characterized by a unique modular structure with receptors divided into several domains
(Tsai and O'Malley, 1994; Beato, 1989; Evans, 1988; Fuller, 1991). They contain a
conserved 66-residue DNA-binding domain and a conserved 240-residue hormonebinding domain. The role of the hormone-binding domain in an intact receptor is to
prevent the DNA-binding domain from interacting with DNA unless hormone is bound.
The amino-terminal domain, which is conserved, enables a receptor to interact with other
transcriptional regulators.

Progestins, estrogens, androgens, and corticosteroids are capable of modifying brain
functions and behaviors by mechanisms that involve the classic genomic model for
steroid action (McEwen et al., 1983). In this model, steroid hormones must enter target
cells to act. It is thought that, because of their lipophilic nature, free steroid hormones
enter the target cells primarily by passive diffusion through the cell membrane. However,
the evidence for the active transport via membrane transporters (Chen and Farese, 1999;
Thompson, 1995) as well as receptor-mediated endocytotic mechanisms is accumulating
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(Kralli et al., 1995; Nykjaer et al., 1999; Adams, 2005; Hammes et al., 2005). Hormones
such as estradiol, progesterone, testosterone, and cortisol traverse the plasma membrane
and bind first to specific receptor proteins in the cytosol. The hormone-receptor
complexes (activated receptors) then migrate to the nucleus, where they bind to specific
DNA sequences called hormone response elements (HREs) and regulate the expression
of nearby genes. The expression of these genes is consequently altered resulting in
promotion (or suppression) of transcription.

Non-genomic effects: The rapid effects of steroids, which occur within seconds or a few
minutes (Brann et al., 1995; McEwen, 1991c) are not compatible with slower genomic
mechanisms involving transcription events (Beato, 1989). The non-genomic effects of
neuroactive steroids are produced mainly via an action on membrane proteins. The most
thoroughly characterized membrane targets have been GABAA and NMDA receptors.
Pharmacological characterizations have demonstrated that both sulfated, as well as nonsulfated neuroactive steroids, act upon these receptors (Gibbs et al., 2006).

GABAA receptor modulation by neuroactive steroids: Whereas certain non-sulfated
neuroactive steroids seem to potentiate the GABAA receptor function, their sulfated
counterparts inhibit these receptors (Park-Chung et al., 1999). For example, 5α-pregnan3α-ol-20-one (3α,5α-THPROG or allopregnanolone) and 5β-pregnan-3α-ol-20-one
(3α,5β-THPROG or pregnanolone) potently prolong the GABA-mediated inhibitory postsynaptic currents at synapses between rat hippocampal neurons in cultures, oocyte
expression system and primary chick spinal cord neurons (Park-Chung et al., 1999;
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Harrison et al., 1987). In contrast, PREGS, DHEAS, as well as the 3α and 3β isomers of
pregnanolone sulfate, inhibit the GABA-induced currents by allosteric modulation of
GABAA receptors at micromolar concentrations (Majewska et al., 1990; Majewska et al.,
1988; Park-Chung et al., 1999). The endogenous progesterone metabolites 3α,5αTHPROG and 3α,5β-THPROG and the deoxycortisone metabolite 5α-pregnan-3α-21-diol
(3α,5α-THDOC) are potent stereoselective positive allosteric modulators of GABAA
receptors (i.e., nanomolar concentrations) (“GABA modulatory effect”) (Callachan et al.,
1987; Peters et al., 1988; Lambert et al., 1995). At relatively higher concentrations
(nanomolar to low micromolar) these steroids directly activate the GABAA receptorchannel complex (“GABA mimetic effect”) (Callachan et al., 1987; Shu et al., 2004) at a
distinct site from the GABA binding site (Ueno et al., 1997). However, the potency varies
widely and is determined by the neuron-type, as well as by subunit composition of
GABAA receptor (Harney et al., 2003; Vicini et al., 2002; Cooper et al., 1999; Brussaard
et al., 1997; Koksma et al., 2003; Belelli et al., 2002).

NMDA receptor modulation by neuroactive steroids: In the instance of NMDA
receptors, sulfated neuroactive steroids appear to be more active than the non-sulfated
ones. The sulfated neurosteroids, PREGS and DHEAS, have been shown to be positive
modulators of NMDA receptors at micromolar concentrations (Wu and Chen, 1997; Wu
et al., 1991). On the other hand PREGS was shown to inhibit the responses to AMPA and
kainate (Wu and Chen, 1997; Wu et al., 1991). The analogs pregnanolone sulfate and
epipregnanolone sulfate, which differs from PREGS primarily by the lack of a C-5 – C-6
double bond, inhibit the NMDA response of chick spinal cord neurons. Surprisingly, the
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pharmacological studies showed that PREGS and epipregnanolone sulfate do not
compete for a common site (Park-Chung et al., 1997). The interactions of steroids with
NMDA receptors have been suggested to be allosteric in mechanism (Bowlby, 1993).
The non-sulfated neurosteroids, e.g., PREG and pregnanolone are without any
modulatory activity at NMDA receptors, which suggests that the negative charge at the
C-3 position may be important for ligand-receptor interaction (Weaver et al., 2000).

Sigma1 receptor modulation by neuroactive steroids: In addition, the direct action on
the activities on both NMDA and GABAA receptors, neuroactive steroids have been
shown to indirectly modulate these receptors by their action on sigma1 (σ1) receptors
(Monnet and Maurice, 2006).

Pharmacotherapeutic potential of Neurosteroids: Based upon the widespread effects
that the neuroactive steroids have on neurotransmission, it is not surprising that their
regulation is associated with various physiological and pathophysiological conditions,
including stress, pregnancy, neural development and ageing (Paul and Purdy, 1992;
Schumacher et al., 2003). In addition to applications in anaesthesia, lower doses of
steroids are found to produce anxiolytic, sedative and hypnotic effects (Eser et al., 2006;
Gasior et al., 1999; Rupprecht, 2003; Goodchild et al., 2001). Data from preclinical and
clinical studies also support the potential efficacy of neuroactive steroids as a novel class
of drugs for the therapeutic management of epilepsy, insomnia and drug dependence
(Gasior et al., 1999; Gee et al., 1995; Rupprecht, 1997; Rupprecht et al., 1996).
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Effects of steroids on glutamate transporters: In addition to their action on receptors,
certain steroids including gonadal steroids and corticosteroids have also been suggested
to play a regulatory role on the glutamate transporters. These include the upregulation of
both EAAT1 and EAAT2 mRNA, protein expression and activity in cultured primary
astrocytes following the administration of estrogen for 72hours (Pawlak et al., 2005).
This effect was sensitive to ICI 182,780 treatment suggesting estrogen action through
nuclear estrogen receptor. The synthetic glucocorticoid, dexamethasone, also produced a
marked increase of EAAT2 (GLT-1) transcription and protein levels in cortical
astrocytes, whereas EAAT1 (GLAST) expression remained unaffected (Zschocke et al.,
2005). Up-regulation of GLT-1 expression was accompanied by an enhanced glutamate
uptake, which could be blocked by the specific GLT-1 inhibitor dihydrokainate. The
promoting effect of dexamethasone on GLT-1 gene expression and function was
abolished by the GR antagonist mifepristone. The stress hormone, corticosterone, has
also been reported to regulate GLT-1 expression in the rat hippocampus (Autry et al.,
2006). GLT-1 mRNA and protein are upregulated in the hippocampus of ADX, increases
that were reversed with administration of physiological levels of GCs, suggesting that
basal levels of GCs provide tonic inhibition of GLT-1 mRNA and protein expression. In
the high-dose corticosterone paradigm, GLT-1 protein was increased throughout the
hippocampus. It has been shown that glucocorticoids like corticosterone and
dexamethasone, but not non-glucococorticoids, are capable of producing a rapid (within
15 min), specific and transient (35-45 min) rise (~155-160%) in glutamate levels in
hippocampus in vivo. These effects are attributed to non-genomic mechanism of action
(Venero and Borrell, 1999).
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In the present work, we report the specific modulation of the EAATs by certain sulfated
neuroactive steroids using C17.2 cells overexpressing EAAT1 and rat primary astrocyte
cultures. We find that simultaneous application of neuroactive steroid pregnenolone
sulfate (PREGS) alters the ability of EAAT1 to transport atypical substrates like Daspartate and L-cysteine.

Chapter 4: Results

Pregnenolone sulfate (PREGS) increases the uptake of 3H-D-Asparate in C17.2 cells
expressing EAAT1
The uptake of D-[3H]-aspartate by C17.2 cells (Snyder et al., 1992; Snyder et al., 1995)
expressing pAM/CAG-hEAAT1 (Esslinger et al., 2005) 24-hour post-transfection is
shown in Figure 4.1. D-Aspartate is routinely used to quantify EAAT activity, as it is a
non-metabolizable substrate of the transporter. The control rates of uptake of D-aspartate
at 10µM were 102±8 pmol/min/mg protein (mean ± s.e.m., n = 65). The C17.2 cells do
not show any inherent Na+-dependent D-[3H]-aspartate uptake activity, as was illustrated
by the untransfected cells. This uptake was predictably blocked by non-selective EAAT
inhibitors like L-β-threo-benzyloxy aspartate (L-β-TBOA) (Shimamoto et al., 1998), Ltrans-2,4-pyrrolidine dicarboxylate (L-trans-2,4-PDC) (Arriza et al., 1997) but not by the
EAAT2-selective inhibitor dihydrokainate (DHK) (Arriza et al., 1994).
When pregnenolone sulfate (PREGS) at 100µM was similarly tested as a competitive
inhibitor, it was found to increase rather than decrease the uptake of D-[3H]-aspartate. As
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Figure 4.1. Effect of EAAT inhibitors on the uptake of D-[3H]-aspartate in C17.2 cells
transfected with pAM/CAG-hEAAT1.
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The uptake of D-[3H]-aspartate was measured in C17.2 cells transfected with
pAM/CAG-hEAAT1 in the presence and absence of known EAAT inhibitors. The
untransfected cells do not show any Na+-dependent uptake (column 1). Control uptake
for 10µM D-[3H]-aspartate was 102 ± 8 pmol/min/mg protein (mean ± S.E.M.). The
inhibitor concentrations were 100µM for DL-TBOA and L-t-2,4-PDC, 250µM for DHK.
The data are the mean ± S. E. M. of n individual experiment each performed in
duplicate. * p<0.0001.
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reported in Figure 4.2, it increased the Na+-dependent uptake of 3H-D-aspartate to 161 ±
3% of control (mean ± s.e.m., n = 63). Significantly, the PREGS (as well as all the
inhibitors) were added simultaneously with D-aspartate. This uptake is EAAT1-mediated,
as it is blocked by non-selective EAAT inhibitors like L-β-TBOA and (2S,4R)-4-methyl
glutamate ((2S,4R)-4MG) (Vandenberg et al., 1997). Untransfected cells do not exhibit
any uptake activity either in the presence or the absence of PREGS.

Only selective sulfated neuroactive steroids stimulate the uptake of D-[3H]-aspartate
by C17.2 cells expressing EAAT1
To determine what other steroids may effect the uptake by EAAT1 in C17.2 cells, we
screened a number of steroids in different salt forms. These steroids were selected based
on their activities at different receptors present within the brain. Thus, DHEAS has been
found to have positive modulatory effects on glutamate NMDA receptors and negative
modulatory effects on GABA receptors (Wu et al., 1990; Wu et al., 1991; Belelli and
Lambert, 2005). The closely related steroids 3α,5α-TH-PROGS (allopregnanolone
sulfate) and 3α,5β-TH-PROGS (pregnanolone sulfate), on the other hand, exhibit
inhibitory effects on NMDA receptors, as well as GABAA receptors (Park-Chung et al.,
1999; Park-Chung et al., 1994; Park-Chung et al., 1997). When tested on C17.2 cells
expressing EAAT1, the structurally related steroids, 3α,5α-TH-PROGS (200±20 %
control, n = 5) and 3α,5β-TH-PROGS (174±19 % control, n =5) produced similar effects
on D-[3H]-aspartate uptake (Figure 4.3). Interestingly, only minimal changes in activity
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Figure 4.2. Potentiation of EAAT1-mediated D-[3H]-aspartate by pregnenolone sulfate
(PREGS)
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The uptake of D-[3H]-aspartate was measured in C17.2 cells transfected with
pAM/CAG-hEAAT1 in the presence and absence of 100µM pregnenolone sulfate
(PREGS). The untransfected cells do not show any Na+-dependent uptake in the presence
of PREGS. Control uptake for 10µM D-[3H]-aspartate was 102 ± 8 pmol/min/mg protein
(mean ± S.E.M.). The inhibitor concentrations were 100µM for DL-TBOA and 2S,4R4MG. * and # represent comparison to the control and PREGS treatment respectively.
The numbers in brackets represent n. p < 0.05.
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Figure 4.3. Potentiation of EAAT1-mediated D-[3H]-aspartate uptake by sulfated steroids
in C17.2 cells.
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The uptake of D-[3H]-aspartate in C17.2 cells transfected with pAM/CAG-hEAAT1 in
the presence and absence of 100µM sulfated steroids. * represents statistically significant
values (p < 0.05) as compared to the control. The numbers in brackets represent n.
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were seen with the addition of dehydroepiendrosterone sulfate (DHEAS), a steroid
having similar effects as PREGS on NMDA receptors, GABA receptors and VGLUTs.
Other sulfated steroids like 1,3,5(10)-estratrien-3-ol-17-one sulfate (ESTS) failed to
effect the uptake of D-[3H]-aspartate by EAAT1. Whereas all the sulfated steroids tested
possess a sulfate group at C-3, they differ in the C-17 substitution and the degree of
unsaturation (Figure 4.4). PREGS and pregnanolone analogs possess acyl group at C-17,
while DHEAS and ESTS have oxygen atom at C-17. The more potent activity observed
with PREGS, 3α,5α-TH-PROGS and 3α,5β-TH-PROGS suggests that the acyl side chain
at C-17 of these steroids may be important for effective interaction with the target site.
The negative charge at C-3 as well as the C-17 substitution have been identified to play
critical roles in interaction of steroid with other proteins, including GABAA receptors
(Hosie et al., 2006), estrogen receptors (Brzozowski et al., 1997), and sex hormonebinding globulin (SHBG) protein (Grishkovshaya et al., 2000). The replacement of
sulfate (SO42-) with another negatively charged group like hemisuccinate at C-3 position
has been shown to retain the activity of the corresponding neuroactive steroids at NMDA
(Weaver et al., 2000) and GABAA receptors (Park-Chung et al., 1999). The interaction at
the C-3 position appears to also play an important role in EAAT1-expressing C17.2 cells.
In this instance, however, the presence of a SO42- group, but not acetate, at C-3 appears to
be required, as the non-sulfated steroids like PREG, PREGA, EST-hemisuccinate
(ESTHem) (at 100µM) were found to have no effect on the uptake of D-aspartate by
EAAT1 (Figure 4.5). The non-sulfated steroids, including: PREG and pregnanolone
derivatives have also been shown to elicit no effect on NMDA-mediated currents or
neurotoxicity in primary rat hippocampal neurons (Weaver et al., 2000).
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Figure 4.4. Structures of common neurosteroids.
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Figure 4.5. Effects of non-sulfated steroids on D-[3H]-aspartate uptake by EAAT1 in
C17.2 cells.
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represent n. The uptake values were found to be statistically non-significant as compared
to control.
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A wide variety of compounds that exhibit some structural characteristics of steroids were
also tested for inhibitory activity, including: 5´-adenosine monophosphate (250µM), 5´guanosine monophosphate (250µM), anandamide (300µM), 5,6-naphthyl quinoline
dicarboxylate (5,6-QDC) (250µM) and 3-nitro-L-tyrosine (100µM) (Figure 4.6). None of
these compounds showed any effect on the uptake of D-[3H]-aspartate on C17.2 cells
expressing EAAT1.

The sulfated steroids exhibit the strongest effects on the uptake by EAAT1
To test if PREGS alters the uptake of D-[3H]-aspartate by other EAATs, C17.2 cells were
transfected with EAAT1, EAAT2 or EAAT3. As seen in figure 4.7, uptake into each of
the transfected cells was sensitive to the inhibition by L-trans-2,4-PDC. In contrast to
their effect on EAAT1, PREGS, 3α,5β-TH-PROGS and 3α,5α-TH-PROGS decreased the
EAAT2-mediated D-[3H]-aspartate uptake to a small but statistically significant degree:
69±6% (n = 6), 80±4% (n = 5) and 80±5% (n = 6) of control, respectively. In the instance
of EAAT3, only PREGS produced a small potentiation that was statistically significant.
ESTS at 100µM was ineffective at all the EAAT subtypes tested. Comparison of percent
control values clearly suggests the most potent effect of the active steroids is on EAAT1mediated D-aspartate uptake.

To confirm that the effect of PREGS on EAAT1 is reproducible in a more
physiologically relevant system, rat primary astrocytes, which predominantly express
EAAT1 (GLAST) (Swanson et al., 1997), were assayed in the presence and absence of
PREGS.
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Figure 4.6. Structures of the compounds tested for their activity at EAAT1-mediated
uptake in C17.2 cells.
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Figure 4.7. Effects of PREGS on the uptake of D-[3H]-aspartate by EAAT1, 2 and 3 in
C17.2 cells.
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Figure 4.8. Effect of PREGS on the uptake of D-[3H]-aspartate by primary astrocyte cells
in culture (PAC).
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The uptake of D-[3H]-aspartate was measured in primary astrocytes. Control uptake for
10µM D-[3H]-aspartate was 165 ± 18 pmol/min/mg protein (mean ± S.E.M., n = 25). The
steroids were used at 100µM. The concentrations of inhibitors were 100µM for DLTBOA and L-glutamate, 250µM for DHK. The data are the mean ± S. E. M. of n
individual experiments each performed in duplicate. * p < 0.05.
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EAAT1 (GLAST) and EAAT2 (GLT-1) are the two subtypes most commonly found on
rat astrocytes (Danbolt, 2001). DHK was used as a negative control to exclude any effects
attributable to EAAT2. As shown in Figure 4.8, the sodium dependent transport in the
primary astrocytes was inhibited by the non-specific EAAT inhibitor, L-trans-2,4-PDC
but not by the EAAT2-selective blocker, DHK. Consistent with our observations in
C17.2 cells, PREGS and 3α, 5β-TH-PROGS, reproducibly stimulated the uptake of D[3H]-aspartate by the primary astrocytes to 153 ± 6% control (mean ± s.e.m., n = 19) and
174 ± 6% control (mean ± s.e.m., n = 11) . It therefore appears that C17.2 cells may be
used as an appropriate mimic of the endogenous system. Two other cell types, HEK293T
cells and Xenopus laevis oocytes, were also examined (Figure 4.9). Surprisingly, PREGS
did not exert any effects on EAAT1-mediated D-aspartate uptake in these cells. This
suggests that the stimulatory acitivity is cell-type specific and that additional mechanisms
and / or interactions may play a role in the observed effects.

The concentration dependence of the activity of PREGS was then examined in greater
detail. The dose-response curves shown in Figures 4.10 and 4.11 reveal that the effect of
PREGS is saturable and exhibits the half-maximal (EC50) values of 8±2µM for C17.2
expressing EAAT1 and 4±1µM for the primary astrocytes.

PREGS effect D-aspartate uptake but not the uptake of other common substrates
The initial studies on the activity of PREGS on EAAT1 were carried out with D-aspartate
as a substrate. This analogue is commonly used in the uptake studies as it negates the
metabolic complications associated with the use of either L-glutamate or L-aspartate.
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Figure 4.9. Effect of PREGS on the uptake of D-[3H]-aspartate in HEK293T cells and
oocytes expressing EAAT1.
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The uptake of D-[3H]-aspartate was measured in HEK293T cells and in oocytes
expressing EAAT1. The concentration of D-aspartate used were 10µM for HEK293T
cells and 100µM for oocytes. PREGS do not appear to alter the activity of EAAT1 for the
uptake of D-[3H]-aspartate in these expression systems. N = 3.
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Figure 4.10. Dose-reponse curve showing potentiation of EAAT1-mediated D-[3H]aspartate uptake by PREGS in C17.2 cells.
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Effects of various concentrations of PREGS on the uptake of 10µM D-aspartate uptake in
C17.2 cells transfected with pAM/CAG-hEAAT1. EC50 values (shown in inset) from the
dose-response curves were generated using a four-parameter Hill function. The data were
fit to the equation: y = a + b*c/(d∧c+x∧c), where a = y min, b = range of transition (y max
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Figure 4.11. Dose-reponse curve showing potentiation of EAAT1-mediated D-[3H]aspartate uptake in primary astrocytes.
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in primary astrocytes. EC50 values (shown in inset) from the dose-response curves were
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Thus, C17.2 cells expressing EAAT1 were assayed for L-glutamate and L-aspartate
uptake in the presence and absence of PREGS. Surprisingly, while PREGS stimulates the
uptake of D-[3H]-aspartate, it minimally effected the uptake of L-[3H]-glutamate or L[3H]-aspartate by EAAT1 (Figure 4.12). The lack of an effect of PREGS on either Laspartate or L-glutamate uptake prompted us to question if the kinetic properties of the
substrates at EAAT1 may influence the observed modulation. To examine this, we first
compared the substrate activities of D-[3H]-aspartate, L-[3H]-aspartate and L-[3H]glutamate under identical conditions (10µM). As shown in Figure 4.13, the accumulation
of L-[3H]-glutamate and L-[3H]-aspartate was greater than that observed with uptake of
D-[3H]-aspartate potentially resulting from differences in either (or both) Km and Vmax
values. Thus, about twice as much L-[3H]-glutamate is transported (217±11% of Daspartate, n = 19) as D-aspartate. The Imax value for D-aspartate uptake has been reported
to be 0.43% relative to that of glutamate (Imax = 1) in oocytes expressing EAAT1 (Arriza
et al., 1994). In the same study, the reported Km values were 48µM and 60µM for Lglutamate and D-aspartate respectively at EAAT1 expressed in COS-1 cells. To further
expand this relationship, the concentration dependence with which EAAT1 transports Lglutamate and D-aspartate were examined in the presence and absence of PREGS. The
kinetic analysis of L-glutamate and D-aspartate uptake illustrated in figures 4.14 and 4.15
yielded a Km value for D-aspartate and L-glutamate of 41±3µM and 19±1µM,
respectively, in C17.2 cells expressing EAAT1. Interestingly, when expressed in C17.2
cells, the Vmax values for L-glutamate and D-aspartate were similar. Non-linear analysis
of the curves reveal that while PREGS does not significantly alter the Vmax for either Lglutamate or D-aspartate uptake, it reduces the Km (21 ± 2µM) for EAAT1-mediated
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Figure 4.12. Effect of PREGS on the EAAT1-mediated uptake of D-[3H]-aspartate, L[3H]-glutamate and L-[3H]-aspartate.
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The effect of 100µM PREGS on the uptake of D-[3H]-aspartate, L-[3H]-glutamate and L[3H]-aspartate, in C17.2 cells transfected with pAM/CAG-hEAAT1. The substrate
concentrations were at 10µM. The control uptake rates for the substrates were (in
pmol/min/mg): 102 ± 8 (mean ± S.E.M., n =65) for D-[3H]-aspartate, 177 ±15 (n = 39)
for L-[3H]-glutamate and 170 ± 33 (n = 7) for L-[3H]-aspartate. The numbers in the
brackets represent n for the PREGS treatment. * (p < 0.05) compared to the respective
control uptake values.
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Figure 4.13. Comparisons of uptake of different substrates in C17.2 cells expressing
hEAAT1.
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uptake of D-[3H]-aspartate . The effect on Km suggests potential allosteric modulation of
the transporter by PREGS. The Km for L-glutamate transport did not change in the
presence or absence of PREGS.

PREGS appears to increase the uptake of D-[3H]-asparatate by direct interaction
with EAAT1
To further characterize the nature of interaction between PREGS and EAAT1-expressing
C17.2 cells, pre-incubation studies were undertaken to examine the effects of variables
such as exposure time and reversibility. As shown in Table 4.1, the 15´ pre-incubation
with PREGS, followed by a 5´ washout, produced virtually no change on the uptake of
D-aspartate. These findings suggest that the effects of PREGS are rapid and reversible.
Moreover, subsequent treatment with PREGS after the washout produced an equivalent
stimulation, further indicating it may be directly interacting with the transporter.

Numerous examples exist that utilize second messenger-mediated mechanisms such as
Ca2+ ions or nitric oxide molecules to regulate transporter activity (Berry et al., 2005;
Duan et al., 1999; Mafra et al., 2002). To investigate if Ca2+ contributed to the observed
changes in the EAAT1-mediated D-aspartate uptake, assays were conducted in Ca2+-free
HBSS uptake buffer containing Ca2+ ion chelator EGTA. As shown in Table 4.2, while
uptake was depressed a small amount in the Ca2+-free conditions, PREGS still increased
the EAAT1-mediated uptake to about 150% of control. Similarly, 60′ preincubation with
L-NAME (NO inhibitor) did not prevent the stimulating effect of PREGS on EAAT1 as
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Figure 4.14. Michelis-Menton kinetics on the uptake of L-[3H]-glutamate in the presence
and absence of PREGS by EAAT1-expressing C17.2 cell.
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A representative plot of concentration dependence of L-[3H]-glutamate uptake in C17.2
cells transfected with pAM/CAG-hEAAT1 in the presence and absence of 100µM
PREGS. The data were analyzed by non-linear curve-fitting to Michelis-Menton
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Figure 4.15. Michelis-Menton kinetics on the uptake of D-[3H]-aspartate in the presence
and absence of PREGS by EAAT1-expressing C17.2 cell.
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A representative plot of concentration dependence of L-[3H]-aspartate uptake in C17.2
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Table 4.1. Effect of 15-minute PREGS preincubation of D-[3H]-aspartate uptake by
C17.2 cells expressing hEAAT1.

Treatment
5´ D-[3H]-aspartate uptake
5´ D-[3H]-aspartate uptake + PREGS
15’ preincubation with 100µM PREGS

Percent of control
100
161 ± 3 ( n = 63) *
100

+ 5´ D-[3H]-aspartate uptake
15’ preincubation with 100µM PREGS

143 ± 5 (n = 5) *

+ 5´ D-[3H]-aspartate uptake + PREGS

C17.2 cell expressing EAAT1 were preincubated with 100µM PREGS for 15´ followed
by a 5´ washout. The uptake of D-[3H]-aspartate was subsequently evaluated in the
presence or absence of simultaneous application of 100µM PREGS for 5´ followed by the
washout. No statistically significant results were obtained when the control uptake rates
for D-[3H]-aspartate , in the preincubation condition (106 ± 4 %, ) and the nonpreincubation conditions, were compared. * (p < 0.05) denotes comparison to the
respective controls.
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Table 4.2. Effect of Ca2+-free conditions on the potentiating effect of PREGS on D-[3H]aspartate uptake by EAAT1-expressing C17.2 cells.

Treatment
5´ D-[3H]-aspartate uptake

Percent of control
100

5´ D-[3H]-aspartate uptake + PREGS

161 ± 3 ( n = 63) *

5´ D-[3H]-aspartate uptake (Ca2+-free)

100

5´ D-[3H]-aspartate uptake + PREGS (Ca2+-free)

152 ± 16 (n = 3) *

The uptake of D-[3H]-aspartate was evaluated in normal and Ca2+-free conditions in the
presence or absence of simultaneous application of 100µM PREGS for 5´. The control
uptake rates for the C17.2 cells in the Ca2+-free conditions were statistically significant
(72 ± 4%, n = 3, p < 0.05, n = 4) when compared to normal conditions. However, 100µM
PREGS stimulated the uptake of D-[3H]-aspartate to the same extent under both
conditions. * (p < 0.05) denotes comparison to the respective controls.
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Table 4.3. Effect of L-NAME preincubation on the potentiating effect of PREGS on D[3H]-aspartate uptake by EAAT1-expressing C17.2 cells.

Treatment
5´ D-[3H]-aspartate uptake
5´ D-[3H]-aspartate uptake + PREGS
5´ D-[3H]-aspartate uptake (L-NAME)
5´ D-[3H]-aspartate uptake + PREGS (L-NAME)

Percent of control
100
161 ± 3 ( n = 63) *
100
205 ± 12 (n = 3) *

C17.2 cells expressing hEAAT1 were preincubated with 100µM L-NAME (NO inhibitor)
for 1 hour. After a 5´ washout, the uptake of D-[3H]-aspartate was evaluated in the
presence or absence of 100µM PREGS for 5´. The control uptake rates for the C17.2 cells
preincubated with L-NAME were statistically non-significant (109 ± 2%, n = 4) when
compared to normal conditions. 100µM PREGS stimulated the uptake of D-[3H]aspartate significantly in both the preincubation and normal conditions. * (p < 0.05)
denotes comparison to the respective controls.
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illustrated in Table 4.3. These results, when combined with rapid and reversible action of
PREGS, further suggest a direct allosteric activity at EAAT1.

PREGS appears to preferentially alter the activity of relatively poor substrates.
The finding that PREGS increased the uptake of D-[3H]-aspartate, but not L-[3H]glutamate suggests that however EAAT1 activity is being modulated, it represents a
change that does not apply equally to all substrates. This led to the hypothesis that
perhaps the action of PREGS on the EAAT1 activity may be dependent upon the
individual kinetic properties of the transporter substrates. This would also be consistent
with the change in Km observed for D-aspartate, but not for L-glutamate. Such a
possibility is supported by the inhibitor data presented in Tables 4.4 and 4.5. Thus, there
was only a minimal change in the level of inhibition produced by DL-β-TBOA on the
uptake of L-[3H]-glutamate in the presence of PREGS. However, in agreement with a
change in the Km for D-aspartate, the level of inhibition of D-[3H]-aspartate uptake
produced by the same amount of DL-β-TBOA was reduced from 7 ± 1% of control (n =
7) to 20 ± 2% of control (n = 7) when PREGS was present. Taken together, these assays
suggest that D-aspartate became a better ligand (i.e., was less sensitive to inhibition by
DL-β-TBOA) in the presence of PREGS.

Another way to address this issue is to determine if the potency of weaker inhibitors also
increase in the presence of PREGS. To investigate this possibility, a series of substrates
were tested for their inhibitor activity against both D-aspartate and L-glutamate in the
presence and absence of PREGS. These included L-serine-o-sulfate (L-SOS) (Arriza et
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al., 1994; Vandenberg et al., 1998b), 2S,4R-4-methyl glutamate (4MG) (Vandenberg et
al., 1997) and L-cysteine (Zerangue and Kavanaugh, 1996b). L-SOS and 4MG have been
shown to act as substrates at EAAT1, but not at EAAT2. 4MG and L-SOS have also been
reported to be substrates of EAAT1 expressed in oocytes with Km value of 54µM and
39µM, respectively. The same study yielded a lower Km value for L-glutamate (Km =
20µM) (Vandenberg et al., 1997; Vandenberg et al., 1998a). The Km value for L-cysteine
(Km = 1.8mM) transport at EAAT1 is much higher in comparison to EAAT2 (Km =
1mM) or EAAT3 (Km = 191µM) in oocytes (Zerangue and Kavanaugh, 1996b). When
these substrates were assayed for their inhibitory activity at EAAT1, each inhibited the
uptake of L-[3H]-glutamate to a greater degree in the presence of PREGS (Tables 4.6,
4.8, 4.10). For example, whereas 4MG at 250µM reduced the uptake of 10µM L-[3H]glutamate to 40 ± 1% of control (mean ± s.e.m., n = 3), it reduced the uptake to a greater
degree (21 ± 2% of control, n = 3) in the presence of PREGS. In contrast, when the same
compounds were tested against D-[3H]-aspartate uptake, the presence of PREGS
produced little change in activity (Tables 4.7, 4.9 and 4.11). Thus, it can be hypothesized
that PREGS had no effect on L-glutamate, but enhanced the binding of L-SOS, Lcysteine and 4MG, thereby increasing their inhibitory activities. On the other hand, since
PREGS also increased the activity of D-aspartate, all of the compounds were similarly
effected and no change in inhibitory activity was observed.

The ability of PREGS to alter the activity of L-cysteine is of particular interest, because it
is found endogenously and serves as an important precursor for glutathione (GSH)
synthesis (Dringen, 2000). Glutathione has been shown to prevent oxidative injury by
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Table 4.4. Effect of DL-β-TBOA on the uptake of L-[3H]-glutamate in the presence and
absence of PREGS in C17.2 cell expressing EAAT1.

Treatment
L-[3H]-glutamate uptake
L-[3H]-glutamate uptake + DL-TBOA
L-[3H]-glutamate + PREGS
L-[3H]-glutamate uptake + PREGS + DL-TBOA

Percent of control
100
21 ± 1 (n = 9) *
100
29 ± 2 (n = 8) * †

EAAT1-mediated uptake of 10µM L-glutamate was significantly inhibited by 100µM
DL-β-TBOA in the presence and absence of 100µM PREGS (* p < 0.05). The
neurosteroid, by itself, slightly inhibited the uptake of L-[3H]-glutamate (88 ± 2, n = 33, p
< 0.05). In the presence of PREGS, the ability of DL-β-TBOA to inhibit the uptake of L[3H]-glutamate is slightly, but significantly, reduced as compared to the uptake in the
presence of DL-β-TBOA alone († p < 0.05).
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Table 4.5. Effect of DL-β-TBOA on the uptake of D-[3H]-aspartate in the presence and
absence of PREGS in C17.2 cell expressing EAAT1.

Treatment
D-[3H]-aspartate uptake
D-[3H]-aspartate uptake + DL-TBOA
D-[3H]-aspartate + PREGS
D-[3H]-aspartate uptake + PREGS + DL-TBOA

Percent of control
100
7 ± 1 (n = 7) *
100
20 ± 2 (n = 7) * †

EAAT1-mediated uptake of 10µM D-glutamate was significantly inhibited by 100µM
DL-β-TBOA in the presence and absence of 100µM PREGS (* p < 0.05). The
neurosteroid, by itself, increased the uptake of D-[3H]-aspartate (161 ± 3, n = 63, p <
0.05). In the presence of PREGS, the ability of DL-β-TBOA to inhibit the uptake of D[3H]-aspartate is significantly reduced as compared to the uptake in the presence of DL-βTBOA alone († p < 0.05).
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several mechanisms (Bains and Shaw, 1997). Whether or not EAATs play a significant
role in the uptake of L-cysteine as a precursor for GSH remains to be determined. To
further investigate the effects of PREGS on L-cysteine activity, we examined whether
there were any changes in the kinetic parameters of D-[3H]-aspartate and L-[3H]glutamate uptake when L-cysteine was included in the presence or absence of PREGS.
As discussed earlier, PREGS decreased the Km for D-aspartate at EAAT1, while the Km
for L-glutamate stayed unaffected (Figures 4.13 and 4.14). When assayed in the presence
of 2mM L-cysteine, PREGS reduced the apparent affinity only for L-glutamate (Figures
4.16 and 4.17). Thus, the Km,app for L-glutamate increased from 21±1µM in the presence
of 2mM L-CSH to 31±1µM in the presence of both L-CSH and PREGS, while the
corresponding Vmax did not significantly change (248±55pmol/min/mg protein to
181±36pmol/min/mg protein). These effects suggest that L-CSH is more potently
competing with L-glutamate in the presence of PREGS than in its absence. In the
instance of D-aspartate, L-CSH (2mM) increased the Km,app from 41±3µM to 60±15µM
at EAAT1, consistent with competitive inhibition. In contrast to what was observed with
L-glutamate, no significant change in these Km,app values were observed in the presence
of PREGS. This suggests that D-aspartate and L-CSH may be similarly effected by the
action of PREGS on EAAT1.

Boudker et al. have identified a lipophilic-binding site in the Pyrococcus horikoshii
glutamate transporter GLTPH crystal structure (Boudker et al., 2007). They speculate that
this may be a potential site of allosteric regulation by lipophilic compounds like
arachidonic acid and other PUFAs including docosahexaenoic acid (DHA) and linolenic
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Table 4.6. Effect of PREGS on the inhibition of L-[3H]-glutamate by 4-MG.

Treatment
L-[3H]-glutamate uptake
L-[3H]-glutamate uptake + 4-MG
L-[3H]-glutamate + PREGS
L-[3H]-glutamate uptake + PREGS + 4-MG

Percent of control
100
40 ± 1 (n = 3) *
100
21 ± 2 (n = 3) * †

EAAT1-mediated uptake of 10µM L-glutamate was significantly inhibited by 100µM 4MG in the presence and absence of 100µM PREGS (* p < 0.05). The neurosteroid, by
itself, slightly inhibited the uptake of L-[3H]-glutamate (88 ± 2, n = 33, p < 0.05). In the
presence of PREGS, the ability of 4-MG to inhibit the uptake of L-[3H]-glutamate was
significantly increased as compared to the uptake in the presence of 4-MG alone († p <
0.05).
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Table 4.7. Effect of PREGS on the inhibition of D-[3H]-aspartate by 4-MG.

Treatment
D-[3H]-aspartate uptake
D-[3H]-aspartate uptake + 4-MG
D-[3H]-aspartate + PREGS
D-[3H]-aspartate uptake + PREGS + 4-MG

Percent of control
100
28 ± 1 (n = 3) *
100
17 ± 2 (n = 3) * †

EAAT1-mediated uptake of 10µM D-aspartate was significantly inhibited by 100µM 4MG in the presence and absence of 100µM PREGS (* p < 0.05). The neurosteroid, by
itself, increased the uptake of D-[3H]-aspartate (161 ± 3, n = 63, p < 0.05). In the
presence of PREGS, the ability of 4-MG to inhibit the uptake of D-[3H]-aspartate was
slightly, but significantly, reduced as compared to the uptake in the presence of 4-MG
alone († p < 0.05).
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Table 4.8. Effect of PREGS on the inhibition of L-[3H]-glutamate by L-SOS in C17.2
cells expressing hEAAT1.

Treatment
L-[3H]-glutamate uptake
L-[3H]-glutamate uptake + L-SOS
L-[3H]-glutamate + PREGS
L-[3H]-glutamate uptake + PREGS + L-SOS

Percent of control
100
18 ± 2 (n = 3) *
100
11 ± 1 (n = 3) * †

250µM L-SOS significantly inhibited the uptake of 10µM L-glutamate in the presence or
absence of 100µM PREGS (* p < 0.05). The neurosteroid, by itself, slightly inhibited the
uptake of L-[3H]-glutamate (88 ± 2, n = 33, p < 0.05). L-SOS inhibited the uptake more
strongly in the presence of PREGS († p < 0.05).
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4.9. Effect of PREGS on the inhibition of D-[3H]-aspartate by L-SOS.

Treatment
D-[3H]-aspartate uptake
D-[3H]-aspartate uptake + L-SOS
D-[3H]-aspartate + PREGS
D-[3H]-aspartate uptake + PREGS + L-SOS

Percent of control
100
11 ± 2 (n = 3) *
100
8 ± 2 (n = 3) *

PREGS by itself has the ability to potentiate the activity of EAAT1 to transport D-[3H]aspartate (161 ± 3, n = 63, p < 0.05). The uptake of 10µM D-aspartate was significantly
inhibited by 250µM L-SOS in the presence and absence of 100µM PREGS (* p < 0.05).
However, PREGS exerted no effect on the ability of L-SOS to inhibit the uptake of D[3H]-aspartate.

132

Table 4.10. Effect of PREGS on the inhibition of L-[3H]-glutamate by L-cysteine (LCSH) in C17.2 cells expressing hEAAT1.

Treatment
L-[3H]-glutamate uptake
L-[3H]-glutamate uptake + L-cysteine
L-[3H]-glutamate + PREGS
L-[3H]-glutamate uptake + PREGS + L-cysteine

Percent of control
100
97 ± 4 (n = 3)
100
74 ± 2 (n = 3) * †

The endogenous substrate, L-cysteine at 1mM, failed to inhibit the uptake of L-[3H]glutamate. PREGS exhibited a slight inhibitory effect on the ability of EAAT1 to
translocated L-glutamate (88 ± .2 % of control, n = 33, p < 0.05). However, the same
concentration of L-cysteine was able to inhibit the uptake in the presence of 100µM
PREGS. This inhibition was statistically significant as compared to the uptake in the
presence of L-cysteine alone (†, p < 0.05) or PREGS alone (*, p < 0.05).
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Table 4.11. Effect of PREGS on the inhibition of D-[3H]-aspartate by L-cysteine (LCSH) in C17.2 cells transfected with hEAAT1.

Treatment
D-[3H]-aspartate uptake
D-[3H]-aspartate uptake + L-cysteine
D-[3H]-aspartate + PREGS
D-[3H]-aspartate uptake + PREGS + L-cysteine

Percent of control
100
89 ± 2 (n = 3) *
100
69 ± 3 (n = 3) *†

PREGS by itself has the ability to potentiate the ability of EAAT1-mediated uptake of D[3H]-aspartate (161 ± 3, n = 63, p < 0.05). The uptake of 10µM D-aspartate was
significantly inhibited by 1mM L-cysteine in the presence and absence of 100µM PREGS
as compared to control (* p < 0.05). The inhibition of D-aspartate uptake by L-cysteine
was significantly increased as compared to the transport of D-aspartate in the presence of
L-cysteine alone.
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Figure 4.16. Michelis-Menton kinetics on L-[3H]-glutamate uptake by EAAT1 in the
presence of PREGS and L-cysteine (L-CSH)
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A representative plot of concentration dependence of L-[3H]-glutamate uptake in C17.2
cells transfected with pAM/CAG-hEAAT1. The data were analyzed by non-linear curvefitting to Michelis-Menton equation, y = m1*x / (m2 + x) The inset shows the Vmax (m1)
and Km (m2) values (mean ± S.E.M.). 100µM PREGS or 2mM L-cysteine did not alter
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either the Km or the Vmax of L-[3H]-glutamate uptake in these cells. However, the Km
significantly reduced (* p < 0.05) from 17 ± 1µM to 31 ± 1µM when the L-glutamate
uptake was measured in the presence of both, PREGS and L-cysteine. The insets,
showing the Km and Vmax values, are placed next to the respective curve.
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Figure 4.17. Michelis-Menton kinetics on D-[3H]-Aspartate uptake by EAAT1 in the
presence of PREGS and L-cysteine (L-CSH).
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A representative plot of concentration dependence of D-[3H]-aspartate uptake in C17.2
cells transfected with pAM/CAG-hEAAT1. The data were analyzed by non-linear curvefitting to Michelis-Menton equation, y = m1*x / (m2 + x) The insets, showing the Vmax
(m1) and Km (m2) values (mean ± S.E.M.), are placed next to the respective curves.
100µM PREGS significantly decreased (* p < 0.05), while 2mM L-cysteine significantly
increased († p < 0.05) the Km for the D-[3H]-aspartate uptake in these cells. The presence
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of PREGS significantly decreased the Km (# p < 0.05) as compared to the control. No
changes were observed in the ability of L-cysteine to inhibit the uptake of D-aspartate in
the presence of PREGS.
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acid (Fairman et al., 1998; Zerangue et al., 1995; Tzingounis et al., 1998). Arachidonic
acid inhibits EAAT1, stimulates EAAT2 and affects the channel properties of EAAT4
(Fairman et al., 1998; Zerangue et al., 1995; Tzingounis et al., 1998). The possibility that
neuroactive steroids might interact with EAAT1 through the similar or related site as
arachidonic acid was tested by using PREGS in the presence and absence of this known
modulator. Whereas arachidonic acid by itself did not show any effect on the uptake of
D-[3H]-aspartate by EAAT1 in C17.2 cells, it did prevent PREGS from stimulating the
uptake of D-[3H]-aspartate when coadministered (Figure 4.18). One possible
interpretation of these results is that arachidonic acid and PREGS may compete for the
same modulatory site on EAAT1.

Chapter 4: Discussion

EAATs are highly regulated proteins. Their modulation has been shown to be mediated
by different mechanisms, including: changes in transcription, translation (Rothstein et al.,
2005; Tian et al., 2007; Su et al., 2003; Figiel et al., 2003; Schlüter et al., 2002; O'Shea et
al., 2006; Thorlin et al., 1998), trafficking (Gonzalez and Robinson, 2004; Hughes et al.,
2004) and allosteric regulation (Vandenberg et al., 2004). In the present work, we have
identified a putative modulatory site on glutamate transporters that can differentially
regulate the function of individual EAAT subtypes. More specifically, we have identified
a series of compounds that alter the transport activity of EAAT1, but not EAAT2 or
EAAT3. The fact that this observed change in activity was produced by neurosteroids
raises questions not only related to the regulatory mechanisms itself, but also to the
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Figure 4.18. Effect of co-presence of PREGS and arachidonic acid on EAAT1-mediated
D-[3H]-aspartate uptake in C17.2 cells.
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The uptake of D-[3H]-aspartate by EAAT1 is significantly increased in the presence of
100µM PREGS in C17.2 cells (161 ± 3% of control, n = 63, * p < 0.05). This increase in
uptake was blocked by the treatment with 300µM arachidonic acid. ** p < 0.05, as
compared to the uptake in the presence of PREGS alone.
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possible role of neurosteroid in modulating glutamate transport. With respect to the
modulatory activity itself, much of the evidence indicating that the effects observed with
the neurosteroids reflect a genuine regulatory mechanism is linked to the issue of
specificity. Thus, a specificity of action was observed among the different EAAT
subtypes, neurosteroids and EAAT substrates.

The neurosteroid, PREGS, was found to significantly increase the uptake of D-[3H]aspartate in C17.2 cells transfected with hEAAT1. It slightly inhibited the uptake D-[3H]aspartate by EAAT2 while minimally affecting the activity of uptake by EAAT3. The
differential modulation of EAATs has also been reported to occur through variety of
other mechanisms. Polyunsaturated fatty acids (PUFAs), as well as Zn2+, have previously
been shown to produce differing effects on the EAAT activities by allosteric mechanisms
(Vandenberg et al., 1998a; Vandenberg et al., 2004). For example, Zn2+ has been shown
to bind and modulate EAATs expressed in oocytes (Mitrovic et al., 2001). Whereas it has
no effects on EAAT2 and EAAT3, Zn2+ was shown to modulate the activity of EAAT1
and EAAT4. It was reported to reduce the glutamate transport by EAAT1 and selectively
inhibit the chloride conductance of EAAT4 without affecting substrate currents.

Evidence that the EAATs are individually regulated also comes from studies focusing on
protein kinase C (PKC). Thus, PKC activation by phorbol ester, phorbol 12-myristate 13acetate (PMA) has been shown to decrease the cell surface expression of GLT-1
(EAAT2) in C6 glioma cells and rat astrocyte-neuron co-cultures (Kalandadze et al.,
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2002; Zhau and Sutherland, 2004). In contrast, the activation of PKC has been reported to
cause a significant increase in both, the cell surface expression and uptake of L-[3H]glutamate, in C6 glioma cells and astrocyte-neuron cocultures (Davis et al., 1998;
Gonzalez et al., 2003; Gonzalez et al., 2002). Importantly, the different PKC subtypes
appear to regulate these transporters by distinct mechanisms. Whereas, PKCα appears to
mediate the redistribution of EAAC1 to the cell membrane by direct interaction of with
EAAC-1 protein (Gonzalez et al., 2003), PKCε seem to increase the intrinsic activity of
this transporter in C6 glioma cells (Gonzalez et al., 2002). In the instance of GLAST
(EAAT1), acute treatment with PMA has been shown to cause ~20% increase in transport
by increasing catalytic efficiency/turnover number of GLAST (Susarla et al., 2004).
Furthermore, EAATs are known to be differentially regulated at the level of protein
synthesis. Several chemical entities, including corticosterone and retinol, have been
identified that stimulate the translation of EAAT2 transcript (Tian et al., 2007).
Additionally, several treatments have been shown to increase the expression of glt1 gene.
These include: treatment with β-lactam antibiotic, ceftriaxone (Rothstein et al., 2005),
certain extracellular factors, such as EGF (Zelenaia et al., 2000), injury-induced growth
factors (TGFα, FGF-2 and PDGF) (Figiel et al., 2003; Schlüter et al., 2002), and
lipopolysaccharide (O'Shea et al., 2006).

The effects of PREGS on the uptake activity of glutamate transporters were reproducibly
observed with only a sub-group of structurally related sulfated steroids. Thus,
pregnanolone sulfate (3α,5β-TH PROGS) and allopregnanolone sulfate (3α,5β-TH
PROGS) also stimulated the uptake of D-[3H]-aspartate by EAAT1. These compounds
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also exhibited an inhibitory effect on EAAT2 and no significant effect on EAAT3mediated transport. DHEAS only slightly potentiated the uptake of D-[3H]-aspartate by
EAAT1 whereas ESTS had no effect. The non-sulfated steroids, including: PREG,
PREGA and ESTH, do not appear to elicit any effect on the uptake activity of EAAT1.
These results suggest that the acyl side chain present on C-17 of PREGS, 3α, 5α-THPROGS and 3α, 5β-TH-PROGS and the presence of C-3 sulfate group may be important
for interaction with the transporter. The introduction of sulfate group at C-3 of
neurosteroids has been shown to have dramatic effects on their activity at GABAA and
NMDA receptors. Whereas, the non-sulfated neurosteroids, 3α, 5α-TH-PROG and 3α,
5β-TH-PROG, are reported to activate the GABA-mediated currents at nanomolar
concentrations (Belelli and Lambert, 2005), their sulfated counterparts are chiefly
negative allosteric modulators of GABAA receptors at micromolar concentrations (Gibbs
et al., 2006; Park-Chung et al., 1999). In the instance of NMDAR, only the sulfated, but
not non-sulfated, steroids were reported to be active in micromolar range (Park-Chung et
al., 1997; Gibbs et al., 2006). The C-17 side chain and C-3 sulfate group have been
identified to be important for the binding of other steroids (Harrison et al., 1987) to a
variety of proteins by means of hydrogen bonding with polar or charged residues within
the protein, e.g., estrogen binding to estrogen receptors (Brzozowski et al., 1997), 5αdihydrotestosterone (5α DHT) binding to sex-hormone-binding globulin (SHBG) protein
(Grishkovshaya et al., 2000) and pregnanolone binding to the GABAA receptors (Hosie et
al., 2006).
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Significantly, the effect of PREGS on EAAT1-mediated activity was also observed in rat
primary astrocytes that endogenously express EAAT1 (GLAST) (Swanson et al., 1997).
EAAT1 is differentially expressed throughout the mammalian brain (Lehre and Danbolt,
1998; Rauen, 2000; Furness and Lehre, 1997; Berger and Hediger, 2000). It has been
shown to be primarily present on astrocytes and is the major glutamate transporter in the
cerebellum, the inner ear, the circumventricular organs and the retina. The disruption of
GLAST transport activity, either by genetic deletion or antisense oligonucleotide
techniques, has been shown to alter the functions of these systems (Maragakis and
Rothstein, 2004). The GLAST knockout mice have been reported to exhibit motor
incoordination and increased susceptibility to cerebellar cold-induced injury (Watase et
al., 1998). Moreover, the intraventricular administration of GLAST antisense
oligonucleotides before the induction of ischemia has been shown to result in an
exacerbation of neuronal injury (Tao et al., 2001). Consistently, the knockdown of
GLAST by the injection of antisense oligonucletide in mice brain has been demonstrated
to produce elevated extracellular glutamate levels, neurodegeneration, and a progressive
motor deficit (paralysis) (Rothstein et al., 1996). Similarly, the GLAST-knockout mice
have shown to increase susceptibility to seizures (Watanabe et al., 1999), exacerbate
hearing loss caused by the increased accumulation of glutamate after acousticoverstimulation (Hakuba et al., 2000) and increase ischemia-induced damage to the retina
(Harada et al., 1998). Thus, the modulation of EAAT1 may play a critical role in the
regulation of several important functions ascribed to these systems such as coordination
and planning of movements, learning motor tasks, balance, hearing and vision (Ghez and
Thach, 2000; Hudspeth, 2000; Tessier-Lavigne, 2000) .
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While PREGS did increase EAAT1 activity in the C17.2 cells and primary astrocytes, it
did not stimulate the activity of EAAT1 in every cell system examined. Thus, PREGS
failed to alter the uptake of D-[3H]-aspartate in HEK293T cells or oocytes expressing
EAAT1. Inherent differences in the lipid composition among cell membranes, as well as
variations in the presence or absence of interacting proteins (London and Brown, 2000;
Simons and Ikonen, 1997) may contribute to different functional responses to PREGS
and related neuroactive steroids (Moore, 2001). Consistent with such idea, the influence
of cell-type on the modulation of EAAT3 by PKC is well documented. In contrast to the
increased expression of EAAT3 in C6 cells and neuron-astrocytes co-cultures, the
activation of PKC by PMA treatment has been reported to downregulate the EAAC1
(EAAT3) surface expression in oocytes (Trotti et al., 2001) and human astrocytoma cell
line U373 (Dunlop et al., 1999).

Surprisingly, the effects of PREGS could not be extended to the uptake of wellrecognized substrates, L-glutamate and L-aspartate. This led us to the idea that
neuroactive steroids may be acting at this site in a way that alters the transport properties
of poor substrates, but has little or no effect on the uptake of good substrates. Previous
studies have demonstrated that EAAT1 transports L-glutamate and L-aspartate with
greater Imax values than that for D-aspartate (Arriza et al., 1994). In this study using C17.2
cells expressing EAAT1, while the Vmax for both L-glutamate and D-aspartate were
similar, the Km values differed significantly. Consistent with these results, the uptake
rates for both L-[3H]-glutamate and L-[3H]-aspartate were higher that those observed for
D-[3H]-aspartate in our experiments. Significantly, the increased transport of D-[3H]-

145

aspartate uptake observed in the presence of PREGS could be ascribed to a significant
decrease in the Km value. Importantly, to make sure the effect of PREGS was not limited
to only D-aspartate, we tested a number of other substrates. Certain other ligands with
substrate activity at EAAT1 appeared to be similarly effected when tested indirectly for a
change in their ability to inhibit the uptake of L-[3H]-glutamate or D-[3H]-aspartate.
Thus, PREGS increased the level of inhibition of L-[3H]-glutamate uptake produced by
4MG, L-SOS and L-cysteine. However, it failed to alter the level of inhibition produced
by these same substrates on the uptake of D-[3H]-aspartate. Furthermore, the presence of
PREGS caused a significant decrease in the inhibition produced by a non-transportable
inhibitor, DL-β-TBOA, on the uptake of D-[3H]-aspartate by EAAT1. Consistent with the
inability of PREGS to alter the inhibitory activities of L-SOS, 4MG or L-cysteine when
assessed against D-aspartate, the neurosteroid also failed to alter the Km,app by L-cysteine
in a more detailed kinetic studies with D-[3H]-aspartate. In contrast, the presence of
PREGS caused an increase in the Km,app value for L-[3H]-glutamate uptake when Lcysteine was used as an inhibitor. This suggests that L-cysteine becomes a better
competitive inhibitor of L-glutamate uptake by EAAT1 in the presence of PREGS.

Consecutive preincubation with PREGS followed by a 5´ washout did not effect the Daspartate uptake in C17.2 cells expressing EAAT1. Only the simultaneous application of
D-[3H]-aspartate and PREGS could produce the observed increase in uptake. Taken
together, these findings support the hypothesis that PREGS interacts directly at a
modulatory site on glutamate transporter protein, EAAT1. As PREGS did not alter the
uptake of L-glutamate, it is possible that the neurosteroid may be only partially active at
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this site, whereas a full “agonist” would be expected to increase the uptake of the
endogenous substrate. In this respect, the neurosteroid may have led to a discovery of a
regulatory site, for which the true physiological ligands have yet to be identified.

However, the fact that PREGS is a neurosteroid and is found endogenously lends another
level of interest to the observed effects. PREGS and DHEAS are among the most
abundant neurosteroids found in mammalian brain, a finding consistent with
neuromodulation. In mammals, glial cells are considered to be a major site of
neurosteroid formation and metabolism in the brain. Both oligodendrocytes and
astrocytes have been identified as primary site for the synthesis of PREGS (Le
Goascogne et al., 2007; Jung-Testas et al., 1989; Baulieu, 1997; Compagnone and
Mellon, 2000). However, newer evidence suggests that neuronal cells may also
participate in the biosynthesis of neurosteroids from cholesterol. For example, Purkinje
cell, a cerebellar neuron, is an active neurosteroidogenic cell, which possesses requisite
enzymes to produce PREG, PREGS and progesterone in several vertebrate species
(Tsutsui et al., 2003). Considering that EAAT1 is the major glutamate transporter in the
cerebellar Bergmann glia, the neurosteroidogenesis in the Purkinje cells is consistent with
the idea that neurosteroids may modulate excitatory neurotransmission in the cerebellum
through an action on EAAT1.

It has been reported that the anterior rat brain contains about 38ng (~80nM) and 16ng
(~35nM) of PREG and PREGS, respectively, per gram of tissue (Corpechot et al., 1983).
This level is much higher than the 1ng/g concentrations reported to be present in plasma.
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Similarly, DHEAS concentrations in the brain have been reported to be much higher in
anterior and posterior rat brain (2ng/g and 5ng/g) as compared to plasma (0.2ng/g)
(Corpechot et al., 1981). In the aged human brain, the concentrations of PREGS and
DHEAS were reported to be about 2ng/g and 13ng/g tissue (Liere et al., 2004). It is
readily acknowledged that these reported concentrations of PREGS are much lower than
the micromolar concentrations found to be effective in the present study. Thus, the
physiological significance of the putative modulatory activity on the EAATs is still
unclear. The micromolar concentrations used in this study are, however, within the same
range at which the sulfated steroids that have been shown to alter the activities of other
targets, such as NMDA and GABAA receptors (Wu et al., 1991; Majewska, 1992; Gibbs
et al., 2006). An issue that has made the concentration-dependence of all of these effects
difficult to interpret, is the inherent problem of quantifying neurosteroids in the
extracellular microenvironment. Thus, the concentration of the neurosteroid may reach
the micromolar levels needed to act at the GABAA, NMDA and possibly the EAATs, if
synthesized or released in local environment surrounding the protein targets.

Interestingly, the effects of PREGS on EAAT1 and 2 are opposite to the effects reported
with arachidonic acid (Zerangue et al., 1995; Fairman et al., 1998; Tzingounis et al.,
1998; Poulsen and Vandenberg, 2001). Micromolar levels of arachidonic acid were found
to inhibit glutamate uptake mediated by EAAT1 by reducing the maximal transport rate
approximately 30%. In contrast, arachidonic acid appears to increase the EAAT2
apparent affinity for glutamate more than 2-fold in oocytes and HEK293 cells (Zerangue
et al., 1995). There is no change in the uptake of glutamate by EAAT4 in the presence of
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arachidonic acid, although it does influence the proton current associated with this
transporter (Fairman et al., 1998; Tzingounis et al., 1998; Poulsen and Vandenberg,
2001). In our experiments, arachidonic acid by itself did not produce any effect on the
uptake of D-aspartate in C17.2 cells expressing EAAT1. However, its simultaneous
application prevented PREGS from stimulating the uptake of 3H-D-aspartate. These
results raise the possibility that arachidonic acid and PREGS may be acting at the same
site. The most straightforward interpretation would suggest that PREGS is acting as an
agonist to stimulate uptake, while arachidonic acid is acting as an antagonist to block its
effect. Such an interpretation, however, does not take into account previous reports that
arachidonic acid acts as an allosteric modulator to inhibit the uptake by EAAT1. In light
of this, one could propose an alternate hypothesis in which arachidonic acid is an agonist
acting to inhibit uptake, while PREGS acts as an antagonist that blocks the effect of
arachidonic acid and restores EAAT1 activity to increased levels. In turn, this would
suggest that arachidonic acid may be acting endogenously in the C17.2 cells and primary
astrocyte cultures to constitutively reduce EAAT1 activity. In such a scenario, the
addition of PREGS as an antagonist would produce the observed increase in activity.
Similarly, if the arachidonic acid is already present, it would provide an explanation as to
why the added arachidonic acid had no effects by itself. Unfortunately, neither of the
mechanisms provides an explanation as to why the PREGS did not alter the uptake of Lglutamate or L-aspartate. Further studies will take an electrophysiological approach and
see if the effects of arachidonic acid on glutamate uptake can be influenced by PREGS.
Initial studies in this proposal tested PREGS by itself on oocytes expressing EAAT1 and
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found no change in activity. It remains to be seen if PREGS would block the inhibitory
activity of arachidonic acid in this same paradigm.

Lastly, in a recent article on the crystal structure of substrate-bound GLTPH, an archeael
EAAT homologue Pyrococcus horikoshii (Boudker et al., 2007), a lipophilic binding site
has been predicted. Curiously, this binding site was apparent in the substrate-bound state
of the transporter but not in non-transportable inhibitor bound state. Given our results of
PREGS on substrates, it is tempting to speculate this might be its site of action on the
EAAT1 protein.
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